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Trent A. Kunkle 
ANTIBIOTIC DISCOVERY TARGETING BACTERIAL GROEL/GROES CHAPERONIN 
SYSTEMS 
The Centers for Disease Control (CDC) and World Health Organizations (WHO) 
have highlighted six species of highly drug-resistant bacteria, commonly termed the 
ESKAPE pathogens, that new antibacterials are urgently needed to treat). The ESKAPE 
pathogens account for over two-million infections and have healthcare costs upwards of 
$20 billion dollars annually. Over the past several decades, pharmaceutical companies 
have drastically reduced their research programs for developing new antibacterial 
agents. As well, bacteria are predisposed to rapidly generate resistance against these 
“me too” drugs, making this strategy a temporary stop-gap in our ability to fight these 
pathogens. This has left the burden to identify new antibiotics that function through 
fundamentally unique mechanisms of action to academia. Towards this goal, we are 
developing a unique antibacterial strategy that functions through targeting the bacterial 
GroEL chaperonin systems. GroEL is a molecular chaperone that helps fold proteins into 
their functional states. Being an essential protein, inhibiting GroEL activity leads to global 
aggregation and bacterial cell death.  
We previously reported a high-throughput screening effort that identified 235 
GroEL inhibitors. A subsequent study with a subset of these inhibitors identified several 
that kill bacteria. To follow-up, we have synthesized 43 analogs of a hit-to-lead molecule, 
compound 1, containing systematic deletions of substituents and substructures to 
determine the essential parts of the scaffold for inhibiting GroEL and killing bacteria. 
Along with inhibiting GroEL, several compound 1 analogs exhibit >50-fold therapeutic 
windows between antibacterial efficacy and cytotoxicity to human liver and kidney cells 
in cell culture. Evaluation of two lead candidates (1 and 11) in a gain-of-resistance assay 
indicated that MRSA bacteria were not able to easily generate resistance to this 
compound class. Compound 1 also exhibited the ability to permeate through already 
vi 
established S. aureus biofilms and maintain its bactericidal effects, whereas vancomycin 
could not. Having established initial structure-activity relationships for the compound 1 
substituents and substructures in this study, future efforts will focus on optimizing the 
antibacterial effects of lead candidates and reducing their off-target toxicity to human 
cells. 
Steven M Johnson, Ph.D., Chair 
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INTRODUCTION 
Bacterial infections and the introduction of antibiotics 
Prior to the 19th century, infectious diseases accounted for nearly half of all 
deaths in the United States (Armstrong 1999). Upon introduction of organized health 
departments, and advancements to sanitation systems, the decline in infection-related 
deaths dropped by nearly half. An initiative then began to combat more aggressive 
cases of infectious disease, in particular, to identify harmful bacterial strains and 
antibiotics that could be administered to kill them in infected patients (Table 1).  Thus 
began the golden era of antibiotic development from 1940-1960 (Davies 2010; Lewis 
2013).  
Table 1. Information on classes of antibiotics (adapted from Lewis, 2013).  
Antibiotic Class Example Mechanism of Action  Target 
Bacteria 
Sulfa drugs  Prontosil Inhibition of dihydropteroate  
synthase 
Gram-positives 
-lactams Penicillin Inhibition of cell wall 
biosynthesis  
Broad-
spectrum  
Aminoglycosides Streptomycin Binding of 30S  
ribosomal subunit 
Broad-
spectrum  
Chloramphenicol Chloramphenicol Binding of 50S  
ribosomal subunit 
Broad-
spectrum  
Macrolides Erythromycin Binding of 50S ribosomal 
subunit 
Broad-
spectrum  
Tetracyclines Chlorotetracycline Binding of 30S ribosomal 
subunit  
Broad-
spectrum  
Rifamycins Rifampicin Binding of RNA polymerase 
-subunit 
Gram-positives  
Glycopeptides Vancomycin Inhibition of cell wall 
biosynthesis  
Gram-positives 
 
Emergence of bacterial resistance to antibiotics  
 Most of the first antibiotics introduced were highly effective against all species of 
bacteria (broad-spectrum); however, some classes were not as potent, or were 
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ineffective, against Gram-negative species. The difference in antibacterial efficacy 
against Gram-positive and Gram-negative bacteria can be attributed to key differences 
in their cellular structure. This is highlighted by their classification as “Gram-negative” 
and “Gram-positive” bacteria, which comes from their ability to retain crystal violet 
staining, which is retained in the presence of peptidoglycan, a polypeptide-cross-linked 
layer making up most of the outer structure in Gram-positive bacteria (Navarre 1999). 
While Gram-negative bacteria do contain a peptidoglycan layer, its abundance is far less 
than that found in Gram-positive. Furthermore, Gram-negative bacteria have a 
lipopolysaccharide (LPS) outer membrane that is impermeable to this stain, as well as 
many antibiotics, making them ineffective (Salton1996). Glycopeptides, for example, 
cannot diffuse across the LPS and are too large to cross porin channels to penetrate into 
Gram-negative bacteria (Nakae 1986; Yarlagadda 2016). Inefficacy across different 
strains can also be attributed to efflux pumps, which actively export molecules from the 
intracellular milieu, preventing antibiotics from being able to effectively engage 
intracellular targets and kill bacteria (Nikaido 1996).  
As research progressed, it became apparent that bacteria had additional intrinsic 
mechanisms to evade the effects of antibiotics. For instance, many bacteria can 
surround themselves in a highly impermeable matrix made up of proteins and 
polysaccharides, known as biofilm. While vancomycin is effective at treating planktonic 
(free-floating) Staphylococcus aureus, it is impermeable to biofilms; thus, S. aureus 
bacteria are able to hide out within these reservoirs until drugs are systemically cleared 
(Stewart 2001; Singh 2010). Biofilm formation has been associated with poor prognosis 
in diseases such as cystic fibrosis, and enhances persistence and spread of infection by 
adhering to tissues and medical devices (Costerton 1999; Musk Jr. 2006). Continued 
presence of these biofilms has been a hallmark to cases of chronic infection, 
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demonstrating increased resistance to treatments through time as they persist 
(Bjarnsholt 2013).  
While innate mechanisms predispose some bacteria to being naturally resistant 
to various classes of antibiotics, a striking observation was noted just a few short years 
after introduction of the early antibiotics: bacterial strains were identified that were 
resistant to what were previously effective drug dosages. Scientists began to realize that 
antibiotic-specific resistance was stemming from two primary mechanisms.  In the first 
mechanism, bacteria were accumulating mutations in their own genes to prevent drugs 
from binding to their targets. An example of this is resistance to quinolone antibiotics, 
where bacteria accumulate mutations in topoisomerases including GyrA, GyrB, ParA, 
and ParC (Eaves 2004). This process raises fitness in cultures exhibiting this genotype, 
thriving where wild-type (WT) strains do not.  
In the second mechanism of resistance, it was found that bacteria can acquire 
new genes from other bacteria through a process called conjugal transfer (Llosa 2002). 
For example, strains of S. aureus have become resistant to vancomycin by acquiring the 
vanA operon from Enterococcus faecalis (Hobbs 1973; Gonzalez-Zorn 2003). In the 
acquisition of this operon, S. aureus can synthesize peptide intermediates that aren’t 
susceptible to vancomycin. These peptide intermediates can then cross-link forming 
peptidoglycan, thus continuing growth. This acquired mechanism of resistance is 
outlined in Figure 1, demonstrating how vancomycin, a reserved antibiotic prescribed 
usually to combat highly resistant bacteria, can be rendered ineffective (Gonzalez-Zorn 
2003; Blue Health Intelligence 2017). In Table 2, antibiotic classes from Table 1 are 
listed, showing the year of introduction, first year of observed resistance, and a brief 
description of the mechanism of resistance.  With many bacteria becoming resistant to 
first-line therapies, it became clear that new antibiotics would need to be developed to 
counter these resistance mechanisms. 
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Figure 1. One potential mechanism whereby bacteria gain antibiotic resistance, with 
vancomycin as an example A. Canonical mechanism of action of vancomycin disrupting 
tripeptide cross-linking by binding to the D-Ala end residue, inhibiting formation of the 
peptidoglycan layer by peptide cross-linking and inducing cell death. B. Conjugal 
transfer of plasmid containing vanA operon to synthesize D-Lac tripeptide, which 
prevents vancomycin binding and thus permits peptidoglycan assembly and bacterial 
proliferation.   
 
Table 2. Information on antibiotic resistance in bacteria (adapted from Giedraitiene 
2011; Lewis 2013)  
Antibiotic Class Year 
Introduced 
Resistance 
Observed 
Mechanism of Resistance 
Sulfa drugs 1936 1942 Mutation altering target binding site, 
reducing affinity 
-lactams 1938 1942 -lactamase facilitated hydrolysis, 
inactivating MOA  
Aminoglycosides 1946 1946 Drugs enzymatically modified, reducing 
their binding affinities  
Chloramphenicol  1948 1950 Reduced binding from antibiotic 
acetylation 
Macrolides 1951 1955 Methylated target binding site, reducing 
affinity 
Tetracyclines 1952 1950 Newly produced proteins binding and 
altering conformation/active site 
Rifamycin 1958 1962 Mutations altering target site/reducing 
affinity 
Glycopeptides 1958 1962 Altered peptidoglycan cross-linking 
 
Emergence of the ESKAPE pathogens and efforts to combat drug resistance  
In 2013, the Centers for Disease Control (CDC) released a report highlighting the 
dangers posed by multi-drug resistant bacteria, in particular a group of six that have 
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been termed the ESKAPE pathogens: Enterococcus faecium (Gram-positive), 
Staphylococcus aureus (Gram-positive), Klebsiella pneumoniae (Gram-negative), 
Acinetobacter baumanii (Gram-negative), Pseudomonas aeruginosa (Gram-negative), 
and the Enterobacter species (Gram-negative). The report estimated these bacteria 
infect over two-million people annually, leading to ~23,000 deaths, despite the 
expenditure of $20 billion for treating these patients.  Of the ESKAPE pathogens, 
methicillin-resistant strains of S. aureus (MRSA) were found to be the deadliest, causing 
~80,000 infections and ~11,000 deaths. These astonishing statistics for once easily 
treatable diseases demonstrate the urgency for developing effective therapeutics that 
may lower the mortality rate. The severity of the ESKAPE pathogens and necessity to 
develop new antibiotics to target them was further reaffirmed by a 2017 report by the 
World Health Organization (WHO).    
 
Figure 2. Number of new antibiotics introduced from 1983-2004 (adapted from Nathan 
2004).  
 
Unfortunately, the development of new antibiotics over the past four decades has 
continually declined (Figure 2, Boucher 2009). In the past 50 years, only two classes of 
synthetic antibiotics (fluoroquinolones and oxazolidinones) and three natural product-
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derived antibiotics (daptomycin, quinupristin, and fidaxomicin) have been introduced 
(Lewis 2013). Some antibiotics were introduced as last resort treatments even though 
resistant strains had already emerged (Wright 2007). Tetracycline, for example, was 
introduced even after resistance was identified two years prior. Drugs such as this may 
continue to be prescribed as they can exhibit synergistic effects when co-administered 
with other antibiotics (Brown 1976). However, the continued push in developing different 
molecules targeting the same pathways allows pre-disposed bacteria to develop 
resistance quickly, as seen with the multi-drug resistant ESKAPE pathogens. Linezolid, 
for example, inhibits protein synthesis by binding to the 50S ribosomal subunit, just as 
erythromycin does. However, whereas it took bacteria over four years to generate 
resistance to erythromycin (introduced in 1951), it took only one year for them to develop 
resistance to linezolid (introduced in 2000) (Lewis 2013). This illustrates the problem of 
how bacteria can quickly develop resistance to drugs that function through a common 
mechanism, despite the drugs being structurally dissimilar. To circumvent pre-disposed 
resistance mechanisms, the need for new antibacterials that function through new 
mechanisms of action and against previously unexploited pathways is necessary.  
A mechanistically unique antibacterial strategy: Targeting the bacterial GroEL 
chaperonin system to disrupt protein folding  
While disrupting protein homeostasis has proven an effective antibacterial 
strategy in the context of inhibiting the assembly of ribosomal or transcriptional 
machinery (Table 1), perturbing protein folding pathways has gone largely unexplored. 
To facilitate newly synthesized polypeptides folding to their active/native structural 
conformations, cells have evolved a class of accessory proteins termed molecular 
chaperones (Hartl 2011). Molecular chaperones, also known as Heat Shock Proteins 
(HSPs), are divided into 5 general classes based on the molecular weights of their 
subunits: HSP100, HSP90, HSP70, HSP60 chaperonins, and Small HSPs (Kumar 
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2015). When molecular chaperone functions are compromised, non-native polypeptides 
misfold and aggregate, which is detrimental to cell viability (Stefani 2004; Maisonneuve 
2008; Carmichael 2000; Bao 2002). Thus, targeting molecular chaperones with small 
molecule inhibitors should be an effective strategy for killing bacteria that is unique from 
the mechanisms of current antibiotics.  
The development of molecular chaperone inhibitors for killing cells is not a new 
concept, as significant efforts have been made developing HSP70 and HSP90 inhibitors 
for treating various cancers. For example, gamitrinib, an HSP90 inhibitor, has shown to 
be effective in synergistic studies with doxorubicin to reduce malignant tumors (Park 
2014; Whitesell 2005). While studies have primarily focused on targeting HSP70 and 
HSP90 for developing anti-cancer agents, some groups have started looking at 
exploiting these chaperones for antibiotic development (Piper 2012). For example, 
Chiappori et al. have recently explored molecules that selectively bind DnaK, the 
bacterial homolog of human HSP70, to disrupt protein folding and kill A. baumanii 
(Chiappori 2015).  
 While research is underway to target HSP70 and HSP90 chaperones as 
antibiotic strategies, targeting HSP60 chaperonin systems, called GroEL chaperonins in 
bacteria, has gone largely unexplored. GroEL functions to refold substrate polypeptides 
through a mechanism unique from other molecular chaperones. GroEL is a homo-
tetradecameric protein that consists of two, seven-membered rings that stack back-to-
back with each other (Figure 3). To facilitate the folding of substrate polypeptides, 
GroEL requires binding of ATP and a co-chaperone, called GroES. GroES binding to the 
GroEL apical domains encapsulates the unfolded polypeptide, where it can attempt to 
fold within the ring and sequestered from the outside environment. A schematic overview 
of this folding process is presented in Figure 4. 
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Figure 3. GroEL/GroES chaperonin structure. GroEL is as a homo-tetradecameric 
complex consisting of two, seven-subunit rings stacked back-to-back. To facilitate 
polypeptide folding, the 7-subunit GroES “lid” encapsulates one of the two rings 
(schematic of the polypeptide folding cycle is shown in Figure 4). Images are adapted 
from the 4V43 and 1SX4 crystal structures. 
 
Figure 4. Schematic of the GroEL/ES 
folding cycle (Horwich 2007). 1. Unfolded 
polypeptide binds to the GroEL apical 
domains, and ATP binds to the GroEL 
equatorial domains. 2. GroES binds to the 
GroEL apical domains and releases the 
unfolded polypeptide into the GroEL cis-
cavity where polypeptide folding occurs. 
3. ATP hydrolysis releases the negative 
cooperativity to the GroEL trans-ring. 4. 
ATP, another unfolded polypeptide, and 
GroES bind to the GroEL trans-ring, 
signaling ejection of cargo from the initial 
cis-ring. The folding cycle continues in the 
new cis-ring.  
 
We hypothesize that blocking 
GroEL folding functions with small molecule inhibitors should be an effective strategy to 
kill bacteria as this chaperonin system is essential for bacterial viability under all 
conditions. Supporting this hypothesis, Chapman et al. previously used a temperature-
9 
sensitive GroEL mutant to study the effects that loss of chaperonin function had on 
Escherichia coli (Chapman 2006). This mutant strain harbors the E461K mutation, 
which, at higher temperatures, disrupts the inter-ring allosteric signaling by ATP binding 
and hydrolysis, locking up the refolding cycle. Compared to E. coli containing WT-
GroEL, bacteria engineered to express the E461K GroEL mutant ceased replicating 2 h 
after shifting to non-permissive temperatures, and were no longer viable after culturing 
for 12 h.  
Because GroEL is conserved across bacteria (Table 3), blocking the chaperonin 
folding cycle should be an effective broad-spectrum antibacterial strategy. A caveat to 
this strategy is that human HSP60 is moderately conserved (48%) with the bacterial 
homologs, which raises the question of potential off-target effects against human cells. 
However, HSP60 is localized within the mitochondrial matrix of human cells, which is 
highly impermeable to penetration by small molecules. Thus, even if compounds can 
inhibit HSP60 in-vitro, they may never reach and inhibit it in the mitochondrial matrix, 
permitting selective targeting of bacteria over human cells (Cheng 1989).  
Table 3. Conservation between GroEL (HSP60) and GroES (HSP10) chaperonins from 
the ESKAPE bacteria and humans. Values represent % identical amino acids compared 
to E. coli GroEL and GroES.  
 
Species GroEL (HSP60) GroES (HSP10) 
E. coli 100% 100% 
E. faecium 57% 47% 
S. aureus 57% 44% 
K. pneumoniae 97% 94% 
A. baumanii 76% 62% 
P. aeruginosa 80% 60% 
E. cloacae 96% 94% 
H. sapiens 48% 35% 
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Previous studies identifying GroEL inhibitors for hit-to-lead development as 
antibacterial candidates  
In a previous study, we performed high-throughput screening to identify inhibitors 
of the GroEL/ES folding cycle (Johnson 2014). A schematic of the general GroEL/ES-
mediated folding assay protocol is outlined in Figure 5.  Briefly, a denatured reporter 
enzyme (typically either -arylsulfotransferase-IV {AST-IV}, malate dehydrogenase 
{MDH}, or rhodanese {Rho}) is mixed to create a binary complex with GroEL. Addition of 
GroES and ATP initiates the folding cycle, and the amount of enzymatic activity by the 
refolded reporter enzyme is monitored.  Thus, this is a coupled assay with reporter 
enzymatic activity being proportional to the functioning of the GroEL/ES chaperonin 
system.  Using this general assay protocol, 235 GroEL inhibitors were identified by 
screening against a library of 700,000 molecules (Johnson 2014).  
 
Figure 5. Schematic of the general GroEL/ES folding assays used for evaluating test 
compounds A. Compounds are added to a binary mixture of GroEL, GroES, and 
unfolded enzyme reporter. ATP is added to initiate the folding cycle, and after a short 
incubation time (15-60 min, depending on the particular enzyme to be folded), EDTA is 
added to quench the cycle. Inhibitors can be added at this point (B) rather than point A, 
to determine inhibition of native enzyme reporter activity. Reporter substrates are added 
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to determine the activity of the reporter enzyme and whether refolding was inhibited or 
not (Johnson 2014). B. Malate Dehydrogenase and C. Rhodanese enzyme reporter 
reactions.  
 
Figure 6. Summary of results from a previous study identifying hit-to-lead 
antibacterial candidates A. Compound 1 exhibits antibacterial effects against S. aureus 
comparable to vancomycin (Van), daptomycin (Dap), and streptomycin (Strep), but does 
show moderate to low cytotoxicity to human liver and kidney cells. Arrows indicate EC50 
values have exceeded the maximum concentrations tested (100 μM).  B. Compound 1 
exhibits bactericidal effects against S. aureus comparable to vancomycin. Figure panels 
have been adapted from Abdeen et al., 2016. C. Compound 1 structure: N-(4-
(Benzo[d]thiazol-2-ylthio)-3-chlorophenyl)-3,5-dibromo-2-hydroxybenzamide. The 
structurally-related compounds, closantel and rafoxanide, are anthelmintic (anti-
parasitic) therapeutics used in veterinary medicine. 
 
A follow-up study further evaluated 22 GroEL inhibitors for their antibacterial 
effects against the ESKAPE pathogens (Abdeen 2016). In that study, compound 1 
(Figure 6C) emerged as a hit-to-lead candidate for further antibacterial development. 
While this compound showed moderate efficacy against A. baumannii, it was largely 
ineffective against the other Gram-negative bacteria tested. This was attributed to a 
combination of the presence of the impermeable LPS membrane of Gram-negative 
bacteria as well as drug efflux. Compound 1 exhibited the greatest efficacy against the 
Gram-positive bacterium, S. aureus, with bactericidal efficacy similar to vancomycin 
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(Figure 6B). While compound 1 exhibits low to moderate cytotoxicity against human 
liver (THLE3) and kidney (HEK 293) cell lines, it still has a >50-fold therapeutic window 
for killing S. aureus bacteria. Intriguingly, two anthelminthic drugs used to treat parasitic 
infections in livestock, closantel and rafoxanide (Figure 6C), bear striking resemblances 
to the compound 1 scaffold (Stromberg 1984). Due to these drugs current use in the field 
of veterinary medicine, this suggests that compound 1 may be an excellent scaffold to 
take forward for further pharmacological optimization as an antibiotic candidate.  
Current study to develop preliminary SAR for the compound 1 scaffold  
While compound 1 itself is a promising GroEL inhibitor to take forward as an 
antibacterial candidate, there is room for further optimization before proceeding into 
proof of principle antibacterial efficacy models in animals (e.g. mice systemically infected 
with S. aureus). As a first step in our optimization strategy, though, rather than adding 
various substituents and substructures to the scaffold as is often done in drug 
development, we chose an opposite approach where we systematically remove the 
various substituents and substructures (R1-R5 – Figure 7) to evaluate each of their 
contributions to inhibitor potency and selectivity. Thus, we synthesized a library of 43 
analogs that contain all the different ± combinations of the R1-R5 groups. We then tested 
them in a series of assays to obtain three primary objectives: 1) determine which groups 
are crucial to inhibit GroEL/ES and HSP60/10 folding function in vitro; 2) identify groups 
that expand the therapeutic window further between antibacterial efficacy and human 
cell cytotoxicity; and 3) determine if this series of molecules are quick to generate 
resistance in bacteria, and if they are effective against bacteria in biofilms. Results from 
these assays would then allow us to identify the smallest effective inhibitor that 
maintains potency against bacteria while reducing cytotoxicity to human cells. Knowing 
this information would then allow us to build upon this base scaffold in a more rational 
approach to improve the pharmacological properties of this antibacterial series.  
13 
 
 
Figure 7. Systematic removal process of compound 1 to synthesize 43 analogs. 
Substituents and substructures (R1-R5) of the parent compound 1 scaffold were 
systematically removed in various combinations, as represented by the dendrogram that 
follows one series of analogs as groups are removed (additional arms/series have been 
removed for clarity). Each tier branches and differentiates from the previous tiered 
molecules, which ultimately generates a library of 43 different analogs.  
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RESULTS AND DISCUSSION 
Identifying the efficacies of compound 1 analogs for inhibiting the GroEL/ES-
mediated folding cycle  
As a first step in this study, we synthesized analogs 1-44 as per the general 
pathways outlined in Scheme 1. Detailed synthetic protocols and compound 
characterizations (e.g. 1H-NMR, MS, and RP-HPLC) are presented in the Experimental 
section. We also purchased the two highly related anthelmintic drugs used in veterinary 
medicine, closantel and rafoxanide, to determine whether they are also able to inhibit the 
GroEL/ES chaperonin system.  While their mode of action is reported to involve 
uncoupling of the proton gradient of oxidative phosphorylation, and thus ATP production 
in the mitochondria of parasites, it is possible that these compounds function through 
other mechanisms of action as well (Martin 1997). Thus, this study is an initial step to 
identify whether or not targeting GroEL/ES (HSP60/10) chaperonin systems may also 
contribute to their anthelmintic properties.  
 
Scheme 1. General procedures to synthesize the compound 1 analog library where the 
R1 to R5 substituents and substructures have been systematically removed. Reagents 
and conditions: a) X = Cl: pyridine, CH2Cl2; b) X = OH: SOCl2, 60°C, then concentrate 
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and add arylamine, pyridine, and CH2Cl2; c) X = OH: DCC, DMAP, CH2Cl2, then add 
arylamine and pyridine; d) X = OH: EDC, HOBt•H2O, TEA, CH2Cl2; e) BBr3, DCM; f) 
K2CO3, EtOH; g) K2CO3, DMF, R.T to 80°C) Tin powder, HCl/AcOH.   
 
Upon successful generation of the analog library, we next employed a series of 
well-established biochemical assays to evaluate compound inhibitory effects against the 
GroEL/ES chaperonin system. As in previous studies (Abdeen 2016; Johnson 2014), 
chaperonin-mediated folding assays were performed using malate dehydrogenase 
(MDH) and rhodanese (Rho) as the unfolded reporter enzymes. Inhibition results for 
testing of compounds in these assays are shown below in Table 4.  
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Table 4. IC50 results for compounds tested in the GroEL/ES-mediated dMDH and dRho 
folding assays, and the native MDH and Rho reporter counter-screens. Log-transformed 
results with standard deviations are found in Table 7 in the Appendix.  
 
Compound Native Rho Native MDH GroEL/ES-dRho GroEL/ES-dMDH
# / Name Reporter Reporter Refolding Refolding
Closantel >100 4.9 1.5 2.1
R1 R2 R3 R4 R5 Rafoxanide >100 13 2.2 2.8
Cl OH Br Br 1 >100 8.8 1.5 1.8
Cl OH Br H 2 >100 >63 3.8 9.5
Cl OH H Br 3 >100 >63 11 37
Cl OH H H 4 >100 >63 63 42
H OH Br Br 5 >100 8.4 1.3 2.7
H OH Br H 6 >100 >63 14 33
H OH H Br 7 >100 >63 30 38
H OH H H 8 >100 >63 87 40
H Cl OH Br Br 9 >100 27 47 24
H Cl OH Br H 10 >100 >63 >100 >100
H Cl OH H Br 11 >100 >63 >100 >100
H Cl OH H H 12 >100 >63 >100 >100
H H OH Br Br 13 >100 51 >100 61
H H OH Br H 14 >100 >63 >100 >100
H H OH H Br 15 >100 >63 >100 >100
H H OH H H 16 >100 >63 >100 >100
Cl H Br Br 17 >100 >63 >100 >100
Cl H Br (H) H (Br) 18 >100 >63 >100 >100
Cl H H H 19 >100 >63 >100 >100
H H Br Br 20 >100 >63 >100 >100
H H Br (H) H (Br) 21 >100 >63 >100 >100
H H H H 22 >100 >63 >100 >100
H Cl H Br Br 23 >100 >63 >100 >100
H Cl H Br (H) H (Br) 24 >100 >63 >100 >100
H Cl H H H 25 >100 >63 >100 >100
H H H Br Br 26 >100 >63 >100 >100
H H H Br (H) H (Br) 27 >100 >63 >100 >100
H H H H H 28 >100 >63 >100 >100
Cl OCH3 Br Br 29 >100 >63 >100 >100
Cl OCH3 Br H 30 >100 >63 >100 >100
Cl OCH3 H Br 31 >100 >63 >100 >100
Cl OCH3 H H 32 >100 >63 >100 >100
H OCH3 Br Br 33 >100 >63 >100 >100
H OCH3 Br H 34 >100 >63 >100 >100
H OCH3 H Br 35 >100 >63 >100 >100
H OCH3 H H 36 >100 >63 >100 >100
H Cl OCH3 Br Br 37 >100 >63 >100 >100
H Cl OCH3 Br H 38 >100 >63 >100 >100
H Cl OCH3 H Br 39 >100 >63 >100 >100
H Cl OCH3 H H 40 >100 >63 >100 >100
H H OCH3 Br Br 41 >100 >63 >100 >100
H H OCH3 Br H 42 >100 >63 >100 >100
H H OCH3 H Br 43 >100 >63 >100 >100
H H OCH3 H H 44 >100 >63 >100 >100
Compound Substituents & Substructures
Biochemical Assay IC50 (mM)
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Figure 8 A. Correlation plot of IC50 values for compounds tested in the GroEL/ES-dMDH 
and dRho refolding assays. B. Correlation plot of IC50 values for compounds tested in 
the native MDH and native Rho reporter enzymatic counter-screens. Results plotted in 
the grey zones represent IC50 values higher than the maximum concentrations listed.  
 
As visualized in the correlation plot in Figure 8A, compounds were nearly 
equipotent at inhibiting in both of the GroEL/ES-mediated folding assays. As we do not 
know where the binding sites are for this series of inhibitors, precise structure-function 
interpretation of the results remains elusive. In general, though, the R1 benzothiazole 
coupled with the R3 hydroxyl are required for compounds to inhibit GroEL/ES-mediated 
folding of the denatured enzymes. Halogenation at the R2 position (Cl) and R4/R5 
positions (Br) increases inhibitor potency, likely through increased hydrophobic 
interactions within the binding cavities. However, the bromines would also serve to lower 
the pKa of the hydroxyl on the salicylate ring, which could further enhance polar 
interactions.  Perhaps not surprisingly, we found that closantel and rafoxanide were, 
indeed, potent GroEL/ES inhibitors, suggesting that targeting chaperonin systems could 
be contributing to their anthelmintic efficacies. We next evaluated compounds for their 
ability to inhibit native MDH and Rho to identify false-positives that simply inhibit the 
enzymatic reporter reactions of the coupled folding assays. Schematics of these assays 
are outlined in Figure 5, with detailed experimental protocols presented in the 
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Experimental section. While some compounds were found to inhibit native MDH (e.g. 1, 
5, closantel, and rafoxanide), none of the analogs were found to inhibit native rhodanese 
enzymatic activity (Table 4 and Figure 8B). These results support that inhibitors are 
inhibiting the chaperonin-mediated folding cycle, although it appears that selectivity 
issues may be a liability that future studies would need to address.  
Determining antibacterial efficacy against the ESKAPE pathogens 
   
We next evaluated compounds for antibacterial efficacy against the ESKAPE 
pathogens in liquid media culture as we previously reported (Abdeen 2016), with one 
primary modification – media was supplemented with 12.5 mg/L of Mg2+ and 25 mg/L 
Ca2+. This was done to more accurately mimic the concentrations of free Mg2+ and Ca2+ 
in vivo, since chelating to divalent cations can alter the antibacterial efficacies of some 
compounds, which is the case for daptomycin. Inhibition results for testing of compounds 
in these bacterial proliferation assays are shown below in Table 5. 
In general, this series of analogs is ineffective against the Gram-negative 
bacteria (K. pneumonia, A. baumannii, P. aeruginosa, E. cloacae), likely owing to drug 
efflux and/or impermeability to the lipopolysaccharide (LPS) outer membranes of Gram-
negative bacteria. However, with regards to A. baumannii, notable exceptions are 
compounds 2 and 6, which exhibit EC50 values of 2.9 and 12 µM, respectively. This 
suggests that these drug efflux and LPS impermeability issues may not be 
insurmountable with further inhibitor optimization. As previously observed with 
compound 1, several analogs retained antibacterial efficacy against the Gram-positive 
bacteria, E. faecium and S. aureus. Strikingly, inhibitors were much more effective at 
killing S. aureus than E. faecium, which has also been noted for other antibiotics. For 
example, quinupristin/dalfopristin is bactericidal against S. aureus, but bacteriostatic 
against E. faecium (Hancock 2005). For our inhibitor series, the presence of the hydroxyl 
at the R3 position appears to be integral for potent inhibition of S. aureus bacteria. With 
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the exception of compound 16, hydroxylation at the R3 position affords potent inhibitors 
of S. aureus proliferation almost regardless of substituents and substructures at the 
other positions. However, it is noted that incorporation of the benzothiazole substructure 
at the R1 position are the most potent inhibitors, with EC50 values in the nanomolar 
range, which may support on-target effects since these analogs are able to inhibit 
GroEL/ES-mediated folding functions. Importantly, these analogs are all equipotent 
against the MRSA strain that we evaluated against.    
When we compare the EC50 results of this series of compounds against E. 
faecium and S. aureus bacteria with the IC50 values obtained in the GroEL/ES-dMDH 
refolding assay (Figure 9), an interesting observation is noted. With respect to E. 
faecium, there is an indication of on-target effects against GroEL/ES driving antibacterial 
activity. However, with MRSA, although a trend is evident between antibacterial efficacy 
and GroEL/ES inhibition, several compounds that are not GroEL/ES inhbitors still remain 
effective against bacteria (e.g. 10-15). While this could indicate potential off-target 
effects, it could also be a result of S. aureus GroEL/ES functioning differently than the E. 
coli GroEL/ES chaperonin system, which we use as a surrogate in these studies. Further 
studies are warranted to determine how E. faecium and S. aureus GroEL/ES function 
compared to E. coli GroEL/ES, and to identify the specific mechanisms of action of these 
inhibitors in both E. faecium and S. aureus bacteria. 
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Table 5. Log(EC50) results for compounds tested in the bacterial proliferation assays. 
Log-transformed results with standard deviations are found in Table 8 in the Appendix. 
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Closantel 1.2 0.47 0.42 >100 >100 >100 >100
R1 R2 R3 R4 R5 Rafoxanide 1.0 0.32 0.30 >100 31 >100 40
Cl OH Br Br 1 0.52 0.36 0.46 >100 66 >100 >100
Cl OH Br H 2 24 0.45 0.55 >100 2.9 >100 >100
Cl OH H Br 3 15 0.12 0.11 >100 >100 >100 >100
Cl OH H H 4 64 0.31 0.42 >100 >100 >100 >100
H OH Br Br 5 0.88 0.44 0.49 >100 >100 >100 >100
H OH Br H 6 8.3 0.76 0.93 >100 11.5 >100 >100
H OH H Br 7 19 0.12 0.13 >100 >100 >100 >100
H OH H H 8 67 0.20 0.34 >100 >100 >100 >100
H Cl OH Br Br 9 15 0.66 1.0 95 46 >100 78
H Cl OH Br H 10 >100 1.3 1.4 >100 >100 >100 >100
H Cl OH H Br 11 >100 0.46 0.46 >100 >100 >100 >100
H Cl OH H H 12 >100 3.1 4.1 >100 >100 >100 >100
H H OH Br Br 13 >100 1.2 1.7 >100 >100 >100 >100
H H OH Br H 14 >100 6.4 8.8 >100 >100 >100 >100
H H OH H Br 15 >100 2.8 4.0 78 >100 >100 >100
H H OH H H 16 >100 28 47 >100 >100 >100 >100
Cl H Br Br 17 >100 >100 >100 >100 >100 >100 >100
Cl H Br (H) H (Br) 18 >100 >100 >100 >100 >100 >100 >100
Cl H H H 19 >100 43 >100 >100 >100 >100 >100
H H Br Br 20 >100 >100 >100 >100 >100 >100 >100
H H Br (H) H (Br) 21 >100 >100 >100 >100 >100 >100 >100
H H H H 22 >100 >100 >100 >100 >100 >100 >100
H Cl H Br Br 23 >100 14 12 >100 >100 >100 >100
H Cl H Br (H) H (Br) 24 >100 47 68 >100 >100 >100 >100
H Cl H H H 25 >100 >100 >100 >100 >100 >100 >100
H H H Br Br 26 >100 >100 >100 >100 >100 >100 >100
H H H Br (H) H (Br) 27 >100 >100 >100 >100 >100 >100 >100
H H H H H 28 >100 >100 >100 >100 >100 >100 >100
Cl OCH3 Br Br 29 >100 >100 >100 >100 >100 >100 >100
Cl OCH3 Br H 30 >100 >100 >100 >100 >100 >100 >100
Cl OCH3 H Br 31 >100 >100 >100 >100 >100 >100 >100
Cl OCH3 H H 32 >100 >100 >100 >100 >100 >100 >100
H OCH3 Br Br 33 >100 >100 >100 >100 >100 >100 >100
H OCH3 Br H 34 >100 >100 >100 >100 >100 >100 >100
H OCH3 H Br 35 >100 >100 >100 >100 >100 >100 >100
H OCH3 H H 36 >100 >100 >100 >100 >100 >100 >100
H Cl OCH3 Br Br 37 >100 46 >100 >100 >100 >100 >100
H Cl OCH3 Br H 38 >100 >100 >100 >100 >100 >100 >100
H Cl OCH3 H Br 39 >100 >100 >100 >100 >100 >100 >100
H Cl OCH3 H H 40 >100 >100 >100 >100 >100 >100 >100
H H OCH3 Br Br 41 >100 >100 >100 >100 >100 >100 >100
H H OCH3 Br H 42 >100 >100 >100 >100 >100 >100 >100
H H OCH3 H Br 43 >100 >100 >100 >100 >100 >100 >100
H H OCH3 H H 44 >100 >100 >100 >100 >100 >100 >100
Ampicillin 9.5 0.11 >100 >100 >100 >100 >100
Minocycline 0.13 0.15 1.2 2 0.1 26 4.4
Rifampicin 6.0 <0.05 0.14 11 1.3 7.8 8.8
Chloramphenicol 6.4 3.3 2.7 2.9 >100 37 2.8
Kanamycin >100 1.1 >100 >100 >100 >100 >100
Streptomycin >100 17 >100 52 >100 >100 >100
Vancomycin 1.2 0.5 0.35 >100 >100 >100 >100
Daptomycin 11 0.53 0.095 >100 >100 >100 >100
Compound Substituents & Substructures
Bacterial Proliferation EC50 /mM
S. aureus
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Figure 9. Correlation plot comparing GroEL/ES-dMDH folding and  
bacterial inhibition results. A. E. faecium proliferation EC50 vs GroEL/ES-dMDH refolding 
IC50 results. B. MRSA proliferation EC50 vs GroEL/ES-dMDH refolding IC50 results.  
 
GroEL inhibitors can also target human HSP60 in vitro, yet display moderate to 
low cytotoxicity to human cells. 
Knowing which compounds were effective GroEL inhibitors with antibacterial 
properties, we next evaluated whether they would inhibit human HSP60 and exhibit 
cytotoxicity to two cell lines that we typically employ for general cytotoxicity testing in 
vitro: THLE3 liver cells and HEK 293 kidney cells. These assays were performed as 
previously reported, with detailed protocols presented in the Experimental section. 
Briefly, the HSP60/10-dMDH folding assay was conducted analogous to the GroEL/ES-
dMDH folding assay so IC50 results could be directly compared. The human cell 
cytotoxicity assays used Alamar blue cell viability reagents to measure the viability of 
liver and kidney cells that had been incubated with test compounds over a 72 h time 
period. Inhibition and cytotoxicity results for these assays are presented in Table 6. 
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Table 6. IC50 and CC50 results for compounds tested in the human HSP60/10-dMDH 
folding assay and the THLE3 and HEK 293 cytotoxicity assays. Log-transformed results 
with standard deviations are found in Table 9 in the Appendix. 
 
 
 
Biochemical 
Assay IC50 (mM)
Compound HSP60/10-dMDH THLE3 HEK 293
# / Name Refolding (Liver) (Kidney)
Closantel 1.5 42 65
R1 R2 R3 R4 R5 Rafoxanide 1.6 23 >100
Cl OH Br Br 1 3.9 15 86
Cl OH Br H 2 5.4 18 63
Cl OH H Br 3 >100 13 36
Cl OH H H 4 >100 29 58
H OH Br Br 5 3.3 19 61
H OH Br H 6 28 38 73
H OH H Br 7 >100 9.9 17
H OH H H 8 >100 27 63
H Cl OH Br Br 9 28 9.5 12
H Cl OH Br H 10 >100 17 15
H Cl OH H Br 11 >100 2.8 2.8
H Cl OH H H 12 >100 14 12
H H OH Br Br 13 61 27 25
H H OH Br H 14 >100 59 58
H H OH H Br 15 >100 16 15
H H OH H H 16 >100 71 81
Cl H Br Br 17 >100 >100 >100
Cl H Br (H) H (Br) 18 >100 88 >100
Cl H H H 19 >100 82 90
H H Br Br 20 >100 >100 >100
H H Br (H) H (Br) 21 >100 82 74
H H H H 22 >100 >100 >100
H Cl H Br Br 23 >100 45 53
H Cl H Br (H) H (Br) 24 >100 50 51
H Cl H H H 25 >100 >100 >100
H H H Br Br 26 >100 >100 >100
H H H Br (H) H (Br) 27 >100 >100 >100
H H H H H 28 >100 >100 >100
Cl OCH3 Br Br 29 >100 >100 >100
Cl OCH3 Br H 30 >100 >100 >100
Cl OCH3 H Br 31 >100 >100 >100
Cl OCH3 H H 32 >100 >100 >100
H OCH3 Br Br 33 >100 >100 >100
H OCH3 Br H 34 >100 >100 >100
H OCH3 H Br 35 >100 >100 >100
H OCH3 H H 36 >100 >100 >100
H Cl OCH3 Br Br 37 >100 >100 >100
H Cl OCH3 Br H 38 >100 >100 >100
H Cl OCH3 H Br 39 >100 94 >100
H Cl OCH3 H H 40 >100 >100 >100
H H OCH3 Br Br 41 >100 >100 >100
H H OCH3 Br H 42 >100 >100 >100
H H OCH3 H Br 43 >100 >100 >100
H H OCH3 H H 44 >100 >100 >100
Compound Substituents & Substructures
Cell Viability CC50 (mM)
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While some analogs selectively inhibit E. coli GroEL over human HSP60 (e.g. 3, 
4, 7, and 8), IC50 values between the GroEL/ES-dMDH and HSP60/10-dMDH folding 
assays were nearly the same for many of the more potent analogs (Figure 10A); 
however, comparison of these results is convoluted by the fact that some of these 
analogs also inhibit native MDH, and thus could be false positives in the HSP60/10-
dMDH folding assay owing to simply inhibiting the MDH reporter reaction.  While HSP60 
inhibition could potentially be teased out by employing dRho as the denatured reporter 
enzyme as we do in the case of the GroEL/ES-dRho folding assay, in our experience, 
the equivalent HSP60/10-dRho folding assay does not provide reliable results, 
potentially owing to the lower stability of human HSP60 compared to E. coli GroEL.  Of 
note when comparing the biochemical and cell-based results is that there does not 
appear to be a noticeable trend between HSP60/10-dMDH folding assay IC50 values 
liver and kidney cytotoxicity assay CC50 values (Figure 10B).  Interestingly, compounds 
that bear the R1 benzothiazole and R3 hydroxyl substructures (1-8) are generally less 
cytotoxic against the HEK 293 cells than their counterparts without the R1 benzothiazole 
(9-16), and also less cytotoxic to the THLE3 liver cells. Since inclusion of these two 
substructures generally afforded potent chaperonin inhibitors, the differences between 
these results may suggest that compound cytotoxicities are predominantly a result of off-
target effects and not from targeting HSP60 itself.  This would not be surprising since 
some analogs are also able to inhibit native MDH (e.g. 1, 5, 9, 13, closantel, and 
rafoxanide).  When comparing EC50 values of compounds inhibiting the proliferation of 
susceptible and methicillin-resistant S. aureus with CC50 values of cytotoxicity against 
the human liver and kidney cells (Figure 11), we note that many analogs exhibit >50-fold 
therapeutic windows. Considering we have only been looking at the effects that 
removing substituents and substructures have on the potency and selectivity of this 
series of analogs (i.e. somewhat of a de-optimization process), these are exciting initial 
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results to move forward from in future med-chem efforts where we begin to append and 
optimize the various substituents and substructures of this scaffold. 
 
 
 
Figure 10. Correlation plots comparing human HSP60/10-dMDH folding inhibition  
results with GroEL/ES-dMDH folding inhibition and human cell cytotoxicity results (A) 
and human cell cytotoxicity (B) results.  
 
 
Figure 11. Correlation plots comparing human cell cytotoxicity results with susceptible 
S. aureus (A) and MRSA (B) proliferation inhibition results.  
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MRSA cannot easily generate resistance to lead analogs  
After identifying which compounds were able to selectively inhibit the GroEL 
chaperonin system and kill bacteria, we next evaluated whether bacteria would be able 
to quickly develop resistance to lead candidate inhibitors.  This was a concern we 
encountered with another series of GroEL inhibitors we have been studying, represented 
by the bis-sulfonamido compound 28R shown in Figure 12B (unpublished results).  For 
this experiment, we adapted a liquid culture resistance assay from the previously 
established procedures of Kim et al. (Kim 2014), and used our MRSA strain as the test 
bacteria. An outline of the general protocol is presented in Figure 12A, with detailed 
procedures presented in the Experimental section. Briefly, test compounds were 
incubated in dilution series with MRSA for 24 h and an EC50 was determined. The first 
well where bacterial growth was >50% was then sub-cultured for another 24 h with test 
compound again in dilution series. Serial passage in this manner was conducted for a 
total of 12 days, each day determining a new EC50 value for the test compound. Test 
compounds that MRSA can rapidly generate resistance to will exhibit increases in their 
EC50 over each successive passage, which was found to be the case for 28R. We 
evaluated two of our lead GroEL inhibitors, 1 and 11, along with vancomycin as a control 
as we have found this strain cannot easily generate resistance to this antibiotic. Over the 
12-day course of this experiment, compounds 1 and 11 exhibited exemplary antibiotic 
efficacy that this MRSA strain was not able to easily generate resistance to. We also 
found that compounds 1 and 11 maintained efficacy against the resistant strain 
generated by 28R in this experiments (results not shown).  
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Figure 12. MRSA Gain-of-resistance assay protocol overview and results. A. General 
protocol of the MRSA gain-of-resistance assay. Each level of wells represents a new 
“passage” of inoculated sample from the previous day. Wells with a black box around 
represent the sample that exhibits viability at the highest compound concentration, which 
will be used to inoculate for the next passage. EC50 values were calculated in each day 
of passage (adapted from Kim et al., 2014) B. Methicillin-resistant S. aureus (MRSA) 
gain-of-resistance assay with a compound from another series (28R), the parent scaffold 
(1), analog 11, and vancomycin. Each passage day is representative of the EC50 values 
recorded prior in the two-fold dilution series of each compound. The final EC50 values 
were recorded at day 12.  
  
Compound 1 is bactericidal to S. aureus within established biofilms 
 
While we found that S. aureus is not able to easily generate resistance to 
compounds 1 and 11, what remained to be seen was whether this series of inhibitors 
would be effective at preventing bacteria from establishing biofilms and be able to kill 
bacteria within established biofilms. Establishing biofilms is another effective mechanism 
by which S. aureus can evade the effects of many current antibiotics, including 
vancomycin.  To gauge the efficacy of lead inhibitor 1 at preventing S. aureus from 
forming biofilms in the first place, we employed an assay similar to the liquid culture 
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assay we used to determine inhibition of bacterial proliferation, with a few modifications 
(detailed procedures presented in the Experimental section). Briefly, compound 1 was 
incubated with S. aureus bacteria in media supplemented with 0.5% glucose (to support 
biofilm formation) for 24 h at 37°C. After 24 h, the supernatant was gently washed from 
the wells, and the biofilm that had formed on the well surface was stained with crystal-
violet and quantified by UV-Vis spectroscopy. We found that both compound 1 and 
vancomycin were able to prevent S. aureus from forming biofilms with EC50 values 
nearly equipotent to antibacterial EC50s we determined against planktonic bacterial 
growth (Figure 13).  This is probably not surprising as compound 1 and vancomycin are 
bactericidal against S. aureus, and thus dead bacteria are not able to form biofilms. 
Next, we evaluated whether or not compound 1 would be bactericidal to S. aureus that 
were within already established biofilms. In this assay, we first grew S. aureus bacteria 
for 24 h in the absence of test compounds so that they could establish biofilms in the 
wells. After 24 h, the cultures were removed, the wells were washed gently, and fresh 
media was added along with compound 1 and vancomycin. The cultures were incubated 
in the presence of test compounds for another 24 h, then the wells were gently washed 
again to remove compound and any planktonic bacteria that had emerged. Fresh media 
was then added and the cultures were incubated for another 24 h to allow any viable 
bacteria remaining in the biofilms to emerge and grow planktonically again. While there 
is about a 7-fold shift in EC50 values for compound 1 killing planktonic bacteria (EC50 = 
0.36 mM) vs. biofilm bacteria (EC50 = 2.4 mM), this is still a very exciting result 
considering vancomycin was completely ineffective against biofilm bacteria, and 
especially since this inhibitor has not yet been optimized from the initial GroEL inhibitor 
hit. Thus, this scaffold shows considerable promise to take forward for further 
development as an antibacterial candidate. 
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Figure 13. Biofilm and growth assay results. Percent inhibition plot showing results from 
biofilm prevention of formation, biofilm penetration, and planktonic growth with the parent 
scaffold (Compound 1) and vancomycin. 
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CONCLUSIONS AND FUTURE DIRECTIONS 
In this study, we developed a series of analogs of the previously identified hit 
GroEL inhibitor, compound 1, and systematically evaluated the contributions that the R1 
to R5 substituents and substructures make to being able to selectively inhibit the 
GroEL/ES chaperonin system and kill bacteria. Potent inhibitors (<10 μM) primarily 
resembled the parent scaffold (1), where a maximum of only one substituent, being 
bromine at R5 or chlorine at R2 or could be removed. It was found that these inhibitors 
correlate closely to disruption of growth in primarily Gram-positive species in the 
ESKAPE pathogens, a correlation not seen in human chaperonin (HSP60/10) inhibition 
vs HEK 293/THLE3 human cell toxicity. Structurally mapping this therapeutic window 
identifies the R3 hydroxyl group facilitating antibacterial efficacy and R1 benzothiazole 
buffering HEK 293/THLE3 toxicity, summarized in Figure 14. Additionally, compound 1 
and vancomycin both did not encounter resistance through an 11-day passage in MRSA, 
maintaining efficacy ≤4 μM. However, it was found S. aureus biofilms are susceptible to 
compound 1 penetration, where vancomycin is not.  This result validates the series as a 
strong antimicrobial hit that can penetrate biofilms, an innate resistance mechanism 
associated with chronic infection.  
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Figure 14. SAR breakdown of compound 1 scaffold. Antibacterial efficacy and human 
cell toxicity breakdown of substituents on the compound 1 scaffold. When groups are not 
represented by “R” it signifies an importance of the drawn group to the labeled 
phenotype. Broken down into 3 tiers, tier 1 (top) shows the parent compound 1. Tier 2 
shows the split between effective antibacterial analogs with a hydroxyl-OH at R3. Tier 3 
shows the split between R4 and R5 positioned bromine to both reduce human cell toxicity 
and enhance A. baumanii efficacy (which also requires benzothiazole as drawn). Tier 3 
also includes an arrow highlighting the importance of benzothiazole to buffer human cell 
toxicity in antibacterial analogs.  
 
In deriving a minimal scaffold that removes unneeded groups from compound 1, 
compounds 2 and 5 are the best inhibitors that omit any substituents. Moving forward in 
the goal of synthesizing an antibiotic, optimization by adding various chemical groups to 
this scaffold will work to retain antibacterial efficacy and minimize any off-target 
toxicities. Future studies will also center around expression and purification of 
chaperonin proteins from ESKAPE pathogens to determine if inhibition correlates to 
efficacy better than utilized E. coli GroEL/ES. Additionally, the detailed mechanism of 
action these inhibitors have on the chaperonin system has yet to be fully elucidated. 
Future experiments centered around binding studies such as isothermal titration 
calorimetry (ITC), X-ray crystallography, and surface plasmon resonance (SPR) will 
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have to be utilized to elucidate a detailed MOA.  Mouse studies with optimized analogs 
in the future will also provide insight into ADME properties for these molecules, as well 
as efficacy within infected animals.  
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EXPERIMENTAL  
Compound Synthesis and Characterization  
Unless otherwise stated, all chemicals were purchased from commercial 
suppliers and used without further purification.  Reaction progress was monitored by 
thin-layer chromatography on silica gel 60 F254 coated glass plates (EM Sciences).  
Flash chromatography was performed using a Biotage Isolera One flash 
chromatography system and eluting through Biotage KP-Sil Zip or Snap silica gel 
columns for normal-phase separations (hexanes:EtOAc gradients) or Snap KP-C18-HS 
columns for reverse-phase separations (H2O:MeOH gradients).  Reverse-phase high-
performance liquid chromatography (RP-HPLC) was performed using a Waters 1525 
binary pump, 2489 tunable UV/Vis detector (254 and 280 nm detection), and 2707 
autosampler.  For preparatory HPLC purification, samples were chromatographically 
separated using a Waters XSelect CSH C18 OBD prep column (part number 
186005422, 130 Å pore size, 5 mm particle size, 19x150 mm), eluting with a H2O:CH3CN 
gradient solvent system.  Linear gradients were run from either 100:0, 80:20, or 60:40 
A:B to 0:100 A:B (A = 95:5 H2O:CH3CN, 0.05% TFA; B = 5:95 H2O:CH3CN, 0.05% TFA.  
Products from normal-phase separations were concentrated directly, and reverse-phase 
separations were concentrated, diluted with H2O, frozen, and lyophilized.  For primary 
compound purity analyses (HPLC-1), samples were chromatographically separated 
using a Waters XSelect CSH C18 column (part number 186005282, 130 Å pore size, 5 
mm particle size, 3.0x150 mm), eluting with the above H2O:CH3CN gradient solvent 
systems.  For secondary purity analyses (HPLC-2) of final test compounds, samples 
were chromatographically separated using a Waters XBridge C18 column (either part 
number 186003027, 130 Å pore size, 3.5 mm particle size, 3.0x100 mm, or part number 
186003132, 130 Å pore size, 5.0 mm particle size, 3.0x100 mm), eluting with a 
33 
H2O:MeOH gradient solvent system.  Linear gradients were run from either 100:0, 80:20, 
60:40, or 20:80 A:B to 0:100 A:B (A = 95:5 H2O:MeOH, 0.05% TFA; B = 5:95 
H2O:MeOH, 0.05% TFA).  Test compounds were found to be >95% in purity from both 
RP-HPLC analyses.  Mass spectrometry data were collected using either an Agilent 
analytical LC-MS at the IU Chemical Genomics Core Facility (CGCF), or a Thermo-
Finnigan LTQ LC-MS in-lab.  1H-NMR spectra were recorded on a Bruker 300 MHz 
spectrometer at the CGCF.  Chemical shifts are reported in parts per million and 
calibrated to the d6-DMSO solvent peaks at 2.50 ppm. 
1: N-(4-(Benzo[d]thiazol-2-ylthio)-3-chlorophenyl)-3,5-
dibromo-2- hydroxybenzamide.  To a stirring mixture of 29 
(51.0 mg, 0.0872 mmol) in anhydrous DCM (5 mL) was 
added BBr3 (0.26 mL of 1 M in DCM, 0.26 mmol).  The reaction was allowed to stir at 
R.T. (under Ar) for 18 h and then quenched with MeOH.  Flash chromatographic 
purification (hexanes:EtOAc gradient) afforded 1 as an off-white solid (34.4 mg, 69% 
yield). 1H-NMR (300 MHz, d6-DMSO) δ 11.14 (br s, 1H), 8.19 (dd, J = 6.2, 2.2 Hz, 2H), 
7.94-8.05 (m, 3H), 7.82-7.89 (m, 2H), 7.47 (td, J = 7.7, 1.3 Hz, 1H), 7.33-7.40 (m, 1H); 
MS (ESI) C20H10Br2ClN2O2S2 [M-H]- m/z expected = 566.8, observed = 566.6; HPLC-1 = 
99%; HPLC-2 = 98%. 
 .......................................................................................................................................... 
2: N-(4-(Benzo[d]thiazol-2-ylthio)-3-chlorophenyl)-3-
bromo-2-hydroxybenzamide.  To a stirring mixture of 30 
(70.4 mg, 0.139 mmol) in anhydrous DCM (5 mL) was added BBr3 (0.42 mL of 1 M in 
DCM, 0.42 mmol).  The reaction was allowed to stir at R.T. (under Ar) for 18 h and then 
quenched with MeOH.  Flash chromatographic purification (hexanes:EtOAc gradient) 
afforded 2 as an off-white solid (53.0 mg, 77% yield). 1H-NMR (300 MHz, d6-DMSO) δ 
12.19 (br s, 1H), 10.93 (s, 1H), 8.22 (d, J = 2.1 Hz, 1H), 7.94-8.03 (m, 3H), 7.81-7.90 (m, 
34 
3H), 7.47 (t, J = 7.6 Hz, 1H), 7.33-7.40 (m, 1H), 6.99 (t, J = 7.9 Hz, 1H); MS (ESI) 
C20H11BrClN2O2S2 [M-H]- m/z expected = 488.9, observed = 488.7; HPLC-1 = 99%; 
HPLC-2 = 99%. 
 .......................................................................................................................................... 
3: N-(4-(Benzo[d]thiazol-2-ylthio)-3-chlorophenyl)-5-
bromo-2-hydroxybenzamide.  To a stirring mixture of 31 
(69.0 mg, 0.136 mmol) in anhydrous DCM (5 mL) was added 
BBr3 (0.41 mL of 1 M in DCM, 0.41 mmol).  The reaction was allowed to stir at R.T. 
(under Ar) for 18 h and then quenched with MeOH.  Flash chromatographic purification 
(hexanes:EtOAc gradient) afforded 3 as an off-white solid (57.4 mg, 86% yield).  1H-
NMR (300 MHz, d6-DMSO) δ 11.47 (br s, 1H), 10.74 (s, 1H), 8.25 (d, J = 2.2 Hz, 1H), 
7.93-8.01 (m, 3H), 7.82-7.89 (m, 2H), 7.60 (dd, J = 8.8, 2.6 Hz, 1H), 7.47 (t, J = 7.1 Hz, 
1H), 7.31-7.39 (m, 1H), 6.99 (d, J = 8.8 Hz, 1H); MS (ESI) C20H11BrClN2O2S2 [M-H]- m/z 
expected = 488.9, observed = 488.7; HPLC-1 = 99%; HPLC-2 = 98%. 
 .......................................................................................................................................... 
4: N-(4-(Benzo[d]thiazol-2-ylthio)-3-chlorophenyl)-2-
hydroxybenzamide.  To a stirring mixture 32 (151 mg, 0.353 
mmol) in anhydrous DCM (5 mL) was added BBr3 (1.06 mL of 
1 M in DCM, 1.06 mmol).  The reaction was allowed to stir at R.T. (under Ar) for 18 h 
and then quenched with MeOH.  Flash chromatographic purification (hexanes:EtOAc 
gradient), followed by preparatory RP-HPLC purification, afforded 4 as an off-white solid 
(100 mg, 69% yield).  1H-NMR (300 MHz, d6-DMSO) δ 11.35 (s, 1H), 10.71 (s, 1H), 8.28 
(d, J = 2.1 Hz, 1H), 7.93-8.00 (m, 2H), 7.83-7.90 (m, 3H), 7.72-7.50 (m, 2H), 7.32-7.38 
(m, 1H), 6.95-7.05 (m, 2H); MS (ESI) C20H12ClN2O2S2 [M-H]- m/z expected = 411.0, 
observed = 410.9; HPLC-1 = 99%; HPLC-2 = >99%. 
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5: N-(4-(Benzo[d]thiazol-2-ylthio)phenyl)-3,5-dibromo-2-
hydroxybenzamide.  To a stirring mixture 33 (123 mg, 
0.223 mmol) in anhydrous DCM (5 mL) was added BBr3 (0.67 mL of 1 M in DCM, 0.67 
mmol).  The reaction was allowed to stir at R.T. (under Ar) for 18 h and then quenched 
with MeOH.  Flash chromatographic purification (hexanes:EtOAc gradient), followed by 
preparatory RP-HPLC purification, afforded 5 as a white solid (72.9 mg, 61% yield).  1H-
NMR (300 MHz, d6-DMSO) δ 12.25-13.00 (br s, 1H), 10.94 (s, 1H), 8.25 (d, J = 2.3 Hz, 
1H), 8.04 (d, J = 2.2 Hz, 1H), 7.88-7.96 (m, 3H), 7.80-7.87 (m, 3H), 7.42-7.48 (m, 1H), 
7.30-7.37 (m, 1H); MS (ESI) C20H11Br2N2O2S2 [M-H]- m/z expected = 532.9, observed = 
532.7; HPLC-1 = 97%; HPLC-2 = >99%. 
 .......................................................................................................................................... 
6: N-(4-(Benzo[d]thiazol-2-ylthio)phenyl)-3-bromo-2-
hydroxybenzamide.  To a stirring mixture 34 (108 mg, 
0.228 mmol) in anhydrous DCM (5 mL) was added BBr3 (0.68 mL of 1 M in DCM, 0.68 
mmol).  The reaction was allowed to stir at R.T. (under Ar) for 18 h and then quenched 
with MeOH.  Flash chromatographic purification (hexanes:EtOAc gradient), followed by 
preparatory RP-HPLC purification, afforded 6 as a tan solid (55.5 mg, 53% yield).  1H-
NMR (300 MHz, d6-DMSO) δ 12.40-12.65 (br s, 1H), 10.96 (s, 1H), 8.05 (dd, J = 8.0, 1.4 
Hz, 1H), 7.90-7.98 (m, 3H), 7.79-7.88 (m, 4H), 7.45 (td, J = 7.7, 1.3 Hz, 1H), 7.30-7.37 
(m, 1H), 6.96 (t, J = 7.9 Hz, 1H); MS (ESI) C20H12BrN2O2S2 [M-H]- m/z expected = 455.0, 
observed = 454.8; HPLC-1 = >99%; HPLC-2 = >99%. 
 .......................................................................................................................................... 
7: N-(4-(Benzo[d]thiazol-2-ylthio)phenyl)-5-bromo-2-
hydroxybenzamide.  To a stirring mixture 35 (90.6 mg, 0.192 
mmol) in anhydrous DCM (5 mL) was added BBr3 (0.58 mL of 1 M in DCM, 0.58 mmol).  
36 
The reaction was allowed to stir at R.T. (under Ar) for 18 h and then quenched with 
MeOH.  Flash chromatographic purification (hexanes:EtOAc gradient), followed by 
preparatory RP-HPLC purification, afforded 7 as a white solid (24.8 mg, 28% yield).  1H-
NMR (300 MHz, d6-DMSO) δ 11.56-11.66 (br s, 1H), 10.65 (s, 1H), 8.00 (d, J = 2.5 Hz, 
1H), 7.90-7.98 (m, 3H), 7.78-7.87 (m, 3H), 7.59 (dd, J = 8.8, 2.5 Hz, 1H), 7.41-7.48(m, 
1H), 7.30-7.37 (m, 1H), 6.99 (d, J = 8.8 Hz, 1H); MS (ESI) C20H12BrN2O2S2 [M-H]- m/z 
expected = 455.0, observed = 454.8; HPLC-1 = 99%; HPLC-2 = >99%. 
 .......................................................................................................................................... 
8: N-(4-(Benzo[d]thiazol-2-ylthio)phenyl)-2-
hydroxybenzamide.  To a stirring mixture 36 (150 mg, 0.382 
mmol) in anhydrous DCM (5 mL) was added BBr3 (1.15 mL of 1 M in DCM, 1.15 mmol).  
The reaction was allowed to stir at R.T. (under Ar) for 18 h and then quenched with 
MeOH.  Flash chromatographic purification (hexanes:EtOAc gradient), followed by 
preparatory RP-HPLC purification, afforded 8 as a white solid (97.3 mg, 67% yield).  1H-
NMR (300 MHz, d6-DMSO) δ 11.47-11.60 (br s, 1H), 10.64 (s, 1H), 7.90-7.98 (m, 4H), 
7.78-7.87 (m, 3H), 7.41-7.49 (m, 2H), 7.29-7.36 (m, 1H), 6.95-7.04 (m, 2H); MS (ESI) 
C20H13N2O2S2 [M-H]- m/z expected = 377.0, observed = 376.9; HPLC-1 = >99%; HPLC-2 
= >99%. 
 .......................................................................................................................................... 
9: 3,5-Dibromo-N-(3-chlorophenyl)-2-hydroxybenzamide.  To a 
stirring mixture 37 (200 mg, 0.476 mmol) in anhydrous DCM (5 mL) 
was added BBr3 (1.45 mL of 1 M in DCM, 1.45 mmol).  The reaction 
was allowed to stir at R.T. (under Ar) for 3 days and then quenched with MeOH.  The 
product was extracted into EtOAc and the organics were rinsed with brine, dried over 
Na2SO4, filtered, and concentrated.  Flash chromatographic purification (hexanes:EtOAc 
gradient) afforded 9 as a tan solid (128 mg, 66% yield).  1H-NMR (300 MHz, d6-DMSO) δ 
37 
12.35-12.80 (br s, 1H), 10.74 (s, 1H), 8.24 (d, J = 2.2 Hz, 1H), 8.03 (d, J = 2.2 Hz, 1H), 
7.85 (t, J = 1.9 Hz, 1H), 7.60-7.67 (m, 1H), 7.43 (t, J = 8.1 Hz, 1H), 7.23-7.29 (m, 1H); 
MS (ESI) C13H7Br2ClNO2 [M-H]- m/z expected = 401.9, observed = 401.7; HPLC-1 = 
97%; HPLC-2 = 97%. 
 .......................................................................................................................................... 
10: 3-Bromo-N-(3-chlorophenyl)-2-hydroxybenzamide.  To a 
stirring mixture 38 (155 mg, 0.455 mmol) in anhydrous DCM (5 mL) 
was added BBr3 (1.35 mL of 1 M in DCM, 1.35 mmol).  The reaction was allowed to stir 
at R.T. (under Ar) for 18 h and then quenched with MeOH.  Reverse-phase flash 
chromatographic purification (H2O:MeOH gradient) afforded 10 as a tan solid (138 mg, 
93% yield).  1H-NMR (300 MHz, d6-DMSO) δ 12.60 (br s, 1H), 10.69 (s, 1H), 8.02 (dd, J 
= 8.0, 1.5 Hz, 1H), 7.87 (t, J = 2.0 Hz, 1H), 7.82 (dd, J = 7.9, 1.4 Hz, 1H), 7.65 (ddd, J = 
8.2, 2.0, 0.9 Hz, 1H), 7.43 (t, J = 8.1 Hz, 1H), 7.25 (ddd, J = 8.0, 2.1, 0.9 Hz, 1H), 6.96 (t, 
J = 7.9 Hz, 1H); MS (ESI) C13H10BrClNO2 [MH]+ m/z expected = 327.96, observed = 
328.10; HPLC-1 = >99%; HPLC-2 = >99%. 
 .......................................................................................................................................... 
11: 5-Bromo-N-(3-chlorophenyl)-2-hydroxybenzamide.  To a stirring 
mixture 39 (205 mg, 0.602 mmol) in anhydrous DCM (5 mL) was added 
BBr3 (1.80 mL of 1 M in DCM, 1.80 mmol).  The reaction was allowed to 
stir at R.T. (under Ar) for 18 h and then quenched with MeOH.  Reverse-phase flash 
chromatographic purification (H2O:MeOH gradient) afforded 11 as a white solid (113 mg, 
58% yield).  1H-NMR (300 MHz, d6-DMSO) δ 11.65 (br s, 1H), 10.50 (s, 1H), 8.00 (d, J = 
2.5 Hz, 1H), 7.91 (t, J = 2.0 Hz, 1H), 7.55-7.64 (m, 2H), 7.40 (t, J = 8.1 Hz, 1H), 7.20 
(ddd, J = 8.0, 2.0, 0.9 Hz, 1H), 6.97 (d, J = 8.8 Hz, 1H); MS (ESI) C13H10BrClNO2 [MH]+ 
m/z expected = 327.96, observed = 328.10; HPLC-1 = >99%; HPLC-2 = >99%. 
 .......................................................................................................................................... 
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12: N-(3-Chlorophenyl)-2-hydroxybenzamide.  To a stirring mixture 40 
(142 mg, 0.543 mmol) in anhydrous DCM (5 mL) was added BBr3 (1.65 
mL of 1 M in DCM, 1.65 mmol).  The reaction was allowed to stir at R.T. 
(under Ar) for 18 h and then quenched with MeOH.  Reverse-phase flash 
chromatographic purification (H2O:MeOH gradient) afforded 12 as an off-white solid (142 
mg, 70% yield).  1H-NMR (300 MHz, d6-DMSO) δ 11.55 (br s, 1H), 10.48 (s, 1H), 7.87-
7.96 (m, 2H), 7.62 (ddd, J = 8.2, 2.0, 1.0 Hz, 1H), 7.36-7.48 (m, 2H), 7.19 (ddd, J = 8.0, 
2.0, 0.9 Hz, 1H), 6.93-7.03 (m, 2H); MS (ESI) C13H11ClNO2 [MH]+ m/z expected = 
248.05, observed = 248.11;  HPLC-1 = >99%; HPLC-2 = >99%. 
 .......................................................................................................................................... 
13: 3,5-Dibromo-2-hydroxy-N-phenylbenzamide.  To a stirring mixture 
41 (149 mg, 0.386 mmol) in anhydrous DCM (5 mL) was added BBr3 
(1.15 mL of 1 M in DCM, 1.15 mmol).  The reaction was allowed to stir at R.T. (under Ar) 
for 3 days and then quenched with MeOH.  The product was extracted into EtOAc and 
the organics were rinsed with brine, dried over Na2SO4, filtered, and concentrated.  
Flash chromatographic purification (hexanes:EtOAc gradient) afforded 13 as a tan solid 
(128 mg, 66% yield).  1H-NMR (300 MHz, d6-DMSO) δ 12.90-13.10 (br s, 1H), 10.65 (s, 
1H), 8.31 (d, J = 2.3 Hz, 1H), 8.03 (d, J = 2.2 Hz, 1H), 7.64-7.71 (m, 2H), 7.38-7.45 (m, 
2H), 7.17-7.24 (m, 1H); MS (ESI) C13H8Br2NO2 [M-H]- m/z expected = 367.9, observed = 
367.7; HPLC-1 = 98%; HPLC-2 = >99%. 
 .......................................................................................................................................... 
14: 3-Bromo-2-hydroxy-N-phenylbenzamide.  To a stirring mixture 
42 (186 mg, 0.608 mmol) in anhydrous DCM (5 mL) was added BBr3 
(1.80 mL of 1 M in DCM, 1.80 mmol).  The reaction was allowed to stir at R.T. (under Ar) 
for 18 h and then quenched with MeOH.  Reverse-phase flash chromatographic 
purification (H2O:MeOH gradient) afforded 14 as a white solid (162 mg, 91% yield).  1H-
39 
NMR (300 MHz, d6-DMSO) δ 13.01 (s, 1H), 10.59 (s, 1H), 8.08 (dd, J = 8.1, 1.4 Hz, 1H), 
7.81 (dd, J = 7.9, 1.4 Hz, 1H), 7.65-7.73 (m, 2H), 7.35-7.45 (m, 2H), 7.14-7.24 (m, 1H), 
6.95 (t, J = 7.9 Hz, 1H); MS (ESI) C13H11BrNO2 [MH]+ m/z expected = 292.0, observed = 
292.1;  HPLC-1 = >99%; HPLC-2 = >99%. 
 .......................................................................................................................................... 
15: 5-Bromo-2-hydroxy-N-phenylbenzamide.  To a stirring mixture 43 
(138 mg, 0.451 mmol) in anhydrous DCM (5 mL) was added BBr3 (1.35 
mL of 1 M in DCM, 1.35 mmol).  The reaction was allowed to stir at R.T. (under Ar) for 
18 h and then quenched with MeOH.  Reverse-phase flash chromatographic purification 
(H2O:MeOH gradient) afforded 15 as a white solid (63.3 mg, 48% yield).  1H-NMR (300 
MHz, d6-DMSO) δ 11.89 (br s, 1H), 10.41 (s, 1H), 8.07 (d, J = 2.5 Hz, 1H), 7.66-7.74 (m, 
2H), 7.58 (dd, J = 8.8, 2.5 Hz, 1H), 7.38 (t, J = 7.9 Hz, 2H), 7.09-7.19 (m, 1H), 6.96 (d, J 
= 8.8 Hz, 1H); MS (ESI) C13H11BrNO2 [MH]+ m/z expected = 292.0, observed = 292.1; 
HPLC-1 = >99%; HPLC-2 = >99%. 
 .......................................................................................................................................... 
16: 2-Hydroxy-N-phenylbenzamide.  To a stirring mixture 44 (153 mg, 
0.673 mmol) in anhydrous DCM (5 mL) was added BBr3 (2.00 mL of 1 M 
in DCM, 2.00 mmol).  The reaction was allowed to stir at R.T. (under Ar) for 18 h and 
then quenched with MeOH.  Reverse-phase flash chromatographic purification 
(H2O:MeOH gradient) afforded 16 as an off-white solid (95.5 mg, 67% yield).  1H-NMR 
(300 MHz, d6-DMSO) δ 11.81 (br s, 1H), 10.39 (s, 1H), 7.96 (dd, J = 7.8, 1.6 Hz, 1H), 
7.67-7.74 (m, 2H), 7.34-7.46 (m, 3H), 7.10-7.17 (m, 1H), 6.93-7.01 (m, 2H); MS (ESI) 
C13H12NO2 [MH]+ m/z expected = 214.1, observed = 214.2; HPLC-1 = >99%; HPLC-2 = 
>99%. 
 .......................................................................................................................................... 
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17: N-(4-(Benzo[d]thiazol-2-ylthio)-3-chlorophenyl)-3,5-
dibromobenzamide.  3,5-Dibromobenzoic acid (175 mg, 
0.624 mmol) was stirred in anhydrous DCM (5 mL) with DCC 
(128 mg, 0.619 mmol) and DMAP (6.5 mg, 0.053 mmol) at R.T. for 1 h (under Ar).  
Compound 46 (150 mg, 0.514 mmol) was then added and the reaction was stirred for an 
additional 18 h.  Flash chromatgraphic purification (hexanes:EtOAc gradient), followed 
by preparatory RP-HPLC purification, afforded 17 as a white solid (101 mg, 35% yield).  
1H-NMR (300 MHz, d6-DMSO) δ 10.83 (br s, 1H), 8.24 (d, J = 2.1 Hz, 1H), 8.13-8.18 (m, 
3H), 7.83-8.01 (m, 4H), 7.47 (td, J = 7.7, 1.3 Hz, 1H), 7.32-7.38 (m, 1H); MS (ESI) 
C20H10Br2ClN2OS2 [M-H]- m/z expected = 550.8, observed = 550.6; HPLC-1 = 98%; 
HPLC-2 = 98%. 
 .......................................................................................................................................... 
18: N-(4-(Benzo[d]thiazol-2-ylthio)-3-chlorophenyl)-3-
bromobenzamide.   3-Bromobenzoyl chloride (81.0 mL, 
0.613 mmol), pyridine (61.0 mL, 0.748 mmol), and compound 46 (151 mg, 0.515 mmol) 
were stirred in anhydrous DCM (5 mL) at R.T. for 18 h (under Ar).  Flash 
chromatographic purification (hexanes:EtOAc gradient) afforded 18 as a pale-yellow 
solid (226 mg, 92% yield).  1H-NMR (300 MHz, d6-DMSO) δ 10.79 ( s, 1H), 8.28 (d, J = 
2.0 Hz, 1H), 8.18 (t, J = 1.8 Hz, 1H), 7.90-8.00 (m, 4H), 7.83-7.88 (m, 2H), 7.54 (t, J = 
7.9 Hz, 1H), 7.43-7.59 (m, 1H), 7.32-7.38 (m, 1H); MS (ESI) C20H11BrClN2OS2 [M-H]- m/z 
expected = 472.9, observed = 472.7; HPLC-1 = 98%; HPLC-2 = 98%. 
 .......................................................................................................................................... 
19: N-(4-(Benzo[d]thiazol-2-ylthio)-3-
chlorophenyl)benzamide.  Benzoyl chloride (71.0 mL, 0.616 
mmol), pyridine (61.0 mL, 0.748 mmol), and compound 46 (153 
41 
mg, 0.522 mmol) were stirred in anhydrous DCM (5 mL) at R.T. for 18 h (under Ar).  
Flash chromatographic purification (hexanes:EtOAc gradient) afforded 19 as a pale-
yellow solid (188 mg, 91% yield).  1H-NMR (300 MHz, d6-DMSO) δ 10.72 ( s, 1H), 8.31 
(d, J = 1.6 Hz, 1H), 7.92-8.03 (m, 5H), 7.86 (d, J = 7.6 Hz, 1H), 7.54-7.67 (m, 3H), 7.43-
7.50 (m, 1H), 7.32-7.38 (m, 1H); MS (ESI) C20H12ClN2OS2 [M-H]- m/z expected = 395.0, 
observed = 394.9; HPLC-1 = 99%; HPLC-2 = 99%. 
 .......................................................................................................................................... 
20: N-(4-(Benzo[d]thiazol-2-ylthio)phenyl)-3,5-
dibromobenzamide.  3,5-Dibromobenzoic acid (120 mg, 
0.428 mmol), compound 47 (85.8 mg, 0.332 mmol), EDC (88.9 mg, 0.464 mmol), 
HOBt•H2O (82.5 mg, 0.539 mmol), and TEA (69.5 mL, 0.499 mmol) were stirred in 
anhydrous DCM (5 mL) at R.T. for 18 h (under Ar).  Flash chromatographic purification 
(hexanes:EtOAc gradient) afforded 20 as an off-white solid (27.2 mg, 16% yield).  1H-
NMR (300 MHz, d6-DMSO) δ 10.73 (s, 1H), 8.17 (d, J = 2.0 Hz, 2H), 8.13-8.15 (m, 1H), 
7.91-8.02 (m, 3H), 7.80-7.87 (m, 3H), 7.42-7.48 (m, 1H), 7.30-7.37 (m, 1H); MS (ESI) 
C20H11Br2N2OS2 [M-H]- m/z expected = 516.9, observed = 516.7; HPLC-1 = >99%; 
HPLC-2 = >99%. 
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21: N-(4-(Benzo[d]thiazol-2-ylthio)phenyl)-3-
bromobenzamide.  3-Bromobenzoyl chloride (65.0 mL, 0.492 
mmol), pyridine (40.0 mL, 0.491 mmol), and compound 47 (116 mg, 0.449 mmol) were 
stirred in anhydrous DCM (5 mL) at R.T. for 18 h (under Ar).  Flash chromatographic 
purification (hexanes:EtOAc gradient) afforded 21 as a white solid (191 mg, 96% yield).  
1H-NMR (300 MHz, d6-DMSO) δ 10.68 (s, 1H), 8.17 (d, J = 1.7 Hz, 1H), 7.96-8.03 (m, 
3H), 7.91-7.95 (m, 1H), 7.79-7.86 (m, 4H), 7.50-7.57 (m, 1H), 7.45 (td, J = 7.7, 1.3 Hz, 
42 
1H), 7.30-7.37 (m, 1H); MS (ESI) C20H12BrN2OS2 [M-H]- m/z expected = 439.0, observed 
= 438.8; HPLC-1 = 99%; HPLC-2 = >99%. 
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22: N-(4-(Benzo[d]thiazol-2-ylthio)phenyl)benzamide.  
Benzoyl chloride (57.0 mL, 0.495 mmol), pyridine (44.0 mL, 
0.540 mmol), and compound 47 (117 mg, 0.451 mmol) were stirred in anhydrous DCM 
(5 mL) at R.T. for 18 h (under Ar).  Flash chromatographic purification (hexanes:EtOAc 
gradient) afforded 22 as a white solid (159 mg, 97% yield).  1H-NMR (300 MHz, d6-
DMSO) δ 10.60 (s, 1H), 7.96-8.04 (m, 4H), 7.90-7.95 (m, 1H), 7.77-7.86 (m, 3H), 7.73-
7.66 (m, 3H), 7.45 (td, J = 7.7, 1.2 Hz, 1H), 7.30-7.37 (m, 1H); MS (ESI) C20H13N2OS2 
[M-H]- m/z expected = 361.1, observed = 361.0; HPLC-1 = >99%; HPLC-2 = 97%. 
 .......................................................................................................................................... 
23: 3,5-Dibromo-N-(3-chlorophenyl)benzamide.  3,5-
Dibromobenzoic acid (299 mg, 1.07 mmol) was stirred in SOCl2 (5 mL) 
at 60°C for 1 h, then was concentrated.  Anhydrous DCM (5 mL), 3-
chloroaniline (94.0 mL, 0.892 mmol), and pyridine (87.0 mL, 1.07 mmol) were added and 
the reaction was stirred at R.T. for 18 h (under Ar).  Flash chromatographic purification 
(hexanes:EtOAc gradient) afforded 23 as an off-white solid (150 mg, 43% yield). 1H-
NMR (300 MHz, d6-DMSO) δ 10.55 (s, 1H), 8.13 (d, J = 1.8 Hz, 2H), 8.02 (d, J = 1.9 Hz, 
1H), 7.92 (t, J = 2.0 Hz, 1H), 7.65-7.71 (m, 1H), 7.40 (t, J = 8.1 Hz, 1H), 7.19 (ddd, J = 
8.0, 2.1, 0.9 Hz, 1H); MS (ESI) C13H9Br2ClNO [MH]+ m/z expected = 389.9, observed = 
390.0; HPLC-1 = 97%; HPLC-2 = 97%. 
 .......................................................................................................................................... 
24: 3-Bromo-N-(3-chlorophenyl)benzamide.  3-Bromobenzoyl 
chloride (0.23 mL, 1.7 mmol), pyridine (0.14 mL, 1.7 mmol), and 3-
43 
chloroaniline (0.15 mL, 1.4 mmol) were stirred in anhydrous DCM (5 mL) at R.T. for 18 h 
(under Ar).  Flash chromatographic purification (hexanes:EtOAc gradient) afforded 24 as 
an off-white solid (338 mg, 77% yield).  1H-NMR (300 MHz, d6-DMSO) δ 10.50 (s, 1H), 
8.14 (t, J = 1.8 Hz, 1H), 7.92-7.98 (m, 2H), 7.78-7.84 (m, 1H), 7.70 (ddd, J = 8.2, 2.0, 0.9 
Hz, 1H), 7.51 (t, J = 8.1 Hz, 1H), 7.39 (t, J = 8.1 Hz, 1H), 7.18 (ddd, J = 8.0, 2.0, 0.9 Hz, 
1H); MS (ESI) C13H10BrClNO [MH]+ m/z expected = 312.0, observed = 312.0; HPLC-1 = 
>99%; HPLC-2 = >99%. 
 .......................................................................................................................................... 
25: N-(3-Chlorophenyl)benzamide.  Benzoyl chloride (0.26 mL, 1.7 
mmol), pyridine (0.19 mL, 2.3 mmol), and 3-chloroaniline (0.20 mL, 2.3 
mmol) were stirred in anhydrous DCM (5 mL) at R.T. for 18 h (under Ar).  
Flash chromatographic purification (hexanes:EtOAc gradient) afforded 25 as an off-white 
solid (414 mg, 94% yield).  1H-NMR (300 MHz, d6-DMSO) δ 10.42 ( s, 1H), 7.93-7.99 (m, 
3H), 7.71 (ddd, J = 8.2, 1.9, 0.9 Hz, 1H), 7.51-7.64 (m, 3H), 7.39 (t, J = 8.1 Hz, 1H), 7.16 
(ddd, J = 8.0, 2.1, 0.9 Hz, 1H); MS (ESI) C13H11ClNO [MH]+ m/z expected = 232.1, 
observed = 232.0;  HPLC-1 = >99%; HPLC-2 = >99%. 
 .......................................................................................................................................... 
26: 3,5-Dibromo-N-phenylbenzamide.  3,5-Dibromobenzoic acid 
(312 mg, 1.11 mmol) was stirred in SOCl2 (5 mL) at 60°C for 1 h, then 
was concentrated.  Anhydrous DCM (5 mL), aniline (85.0 mL, 0.931 mmol), and pyridine 
(90.0 mL, 1.10 mmol) were added and the reaction was stirred at R.T. for 18 h (under 
Ar).  Flash chromatographic purification (hexanes:EtOAc gradient) afforded 26 as a 
white solid (224 mg, 68% yield). 1H-NMR (300 MHz, d6-DMSO) δ 10.42 (s, 1H), 8.14 (d, 
J = 1.7 Hz, 2H), 8.07-8.11 (m, 1H), 7.72-7.78 (m, 2H), 7.33-7.41 (m, 2H), 7.09-7.16 (m, 
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1H); MS (ESI) C13H10Br2NO [MH]+ m/z expected = 355.9, observed = 356.0;  HPLC-1 = 
>99%; HPLC-2 = >99%. 
 .......................................................................................................................................... 
27: 3-Bromo-N-phenylbenzamide.  3-Bromobenzoyl chloride (0.17 
mL, 1.3 mmol), pyridine (0.11 mL, 1.3 mmol), and aniline (0.10 mL, 1.1 
mmol) were stirred in anhydrous DCM (5 mL) at R.T. for 18 h (under Ar).  Flash 
chromatographic purification (hexanes:EtOAc gradient) afforded 27 as a white solid (289 
mg, 95% yield).  1H-NMR (300 MHz, d6-DMSO) δ 10.35 (s, 1H), 8.14 (t, J = 1.8 Hz, 1H), 
7.95 (dt, J = 7.8, 1.3 Hz, 1H), 7.73-7.83 (m, 3H), 7.50 (t, J = 7.9 Hz, 1H), 7.32-7.39 (m, 
2H), 7.08-7.16 (m, 1H); MS (ESI) C13H11BrNO [MH]+ m/z expected = 276.0, observed = 
276.1; HPLC-1 = 98%; HPLC-2 = 98%. 
 .......................................................................................................................................... 
28: N-Phenylbenzamide.  Benzoyl chloride (0.30 mL, 2.6 mmol), 
pyridine (0.22 mL, 2.7mmol), and aniline (0.20 mL, 2.2 mmol) were stirred 
in anhydrous DCM (5 mL) at R.T. for 18 h (under Ar).  Flash chromatographic 
purification (hexanes:EtOAc gradient) afforded 28 as a white solid (367 mg, 85% yield).  
1H-NMR (300 MHz, d6-DMSO) δ 10.26 (s, 1H), 7.93-7.98 (m, 2H), 7.75-7.81 (m, 2H), 
7.49-7.63 (m, 3H), 7.32-7.39 (m, 2H), 7.06-7.13 (m, 1H); MS (ESI) C13H12NO [MH]+ m/z 
expected = 198.1, observed = 198.0; HPLC-1 = >99%; HPLC-2 = >99%. 
 .......................................................................................................................................... 
29: N-(4-(Benzo[d]thiazol-2-ylthio)-3-chlorophenyl)-3,5-
dibromo-2-methoxybenzamide.  Compound 48 (225 mg, 
0.726 mmol) was stirred in SOCl2 (2 mL) at 60°C for 1 h, then 
was concentrated.  Anhydrous DCM (5 mL), compound 46 (148 mg, 0.505 mmol), and 
pyridine (62.0 mL, 0.760 mol) were added and the reaction was stirred at R.T. for 18 h 
(under Ar).  Flash chromatographic purification (hexanes:EtOAc gradient) afforded 29 as 
45 
a yellow solid (58.6 mg, 20% yield). 1H-NMR (300 MHz, d6-DMSO) δ 11.00 (s, 1H), 8.21 
(d, J = 2.1 Hz, 1H), 8.10 (d, J = 2.3 Hz, 1H), 7.97 (t, J = 8.3 Hz, 2H), 7.82-7.87 (m, 2H), 
7.78 (dd, J = 8.6, 2.2 Hz, 1H), 7.47 (td, J = 7.7, 1.3 Hz, 1H), 7.32-7.38 (m, 1H), 3.84 (s, 
3H); MS (ESI) C21H12Br2ClN2O2S2 [M-H]- m/z expected = 580.8, observed = 580.7; 
HPLC-1 = >99%; HPLC-2 = >99%. 
 .......................................................................................................................................... 
30: N-(4-(Benzo[d]thiazol-2-ylthio)-3-chlorophenyl)-3-
bromo-2-methoxybenzamide.  3-Bromo-2-methoxybenzoic 
acid (171 mg, 0.741 mmol) was stirred in SOCl2 (2 mL) at 60°C for 1 h, then was 
concentrated.  Anhydrous DCM (5 mL), compound 46 (170 mg, 0.581 mmol), and 
pyridine (60.5 mL, 0.742 mol) were added and the reaction was stirred at R.T. for 18 h 
(under Ar).  Flash chromatographic purification (hexanes:EtOAc gradient) afforded 30 as 
a yellow solid (48.6 mg, 17% yield). 1H-NMR (300 MHz, d6-DMSO) δ 10.94 (s, 1H), 8.24 
(d, J = 2.1 Hz, 1H), 7.93-8.00 (m, 2H), 7.79-7.87 (m, 3H), 7.61 (dd, J = 7.6, 1.6 Hz, 1H), 
7.47 (td, J = 7.7, 1.3 Hz, 1H), 7.32-7.39 (m, 1H), 7.24 (t, J = 7.8 Hz, 1H), 3.84 (s, 3H); 
MS (ESI) C21H13BrClN2O2S2 [M-H]- m/z expected = 502.9, observed = 502.7; HPLC-1 = 
98%; HPLC-2 = 98%. 
 .......................................................................................................................................... 
31: N-(4-(Benzo[d]thiazol-2-ylthio)-3-chlorophenyl)-5-
bromo-2-methoxybenzamide.  Compound 49 (1.13 g, 4.88 
mmol) was stirred in SOCl2 (3 mL) at 60°C for 1 h, then was 
concentrated.  Anhydrous DCM (10 mL), compound 46 (1.18 g, 4.04 mmol), and pyridine 
(0.49 mL, 6.0 mmol) were added and the reaction was stirred at R.T. for 18 h (under Ar).  
The reaction was then diluted into hexanes and the precipitate was filtered, rinsed with 1 
M HCl and water, and dried.  Flash chromatographic purification (hexanes:EtOAc 
gradient) afforded 31 as a yellow solid (1.80 g, 88% yield).  1H-NMR (300 MHz, d6-
46 
DMSO) δ 10.70 (s, 1H), 8.22 (d, J = 2.0 Hz, 1H), 7.93-7.99 (m, 2H), 7.80-7.87 (m, 2H), 
7.67-7.76 (m, 2H), 7.47 (td, J = 7.7, 1.3 Hz, 1H), 7.32-7.38 (m, 1H), 7.19 (d, J = 8.8 Hz, 
1H), 3.89 (s, 3H); MS (ESI) C21H13BrClN2O2S2 [M-H]- m/z expected = 502.9, observed = 
502.7; HPLC-1 = 98%; HPLC-2 = 98%. 
 .......................................................................................................................................... 
32: N-(4-(Benzo[d]thiazol-2-ylthio)-3-chlorophenyl)-2-
methoxybenzamide.  2-Methoxybenzoic acid (151 mg, 0.990 
mmol) was stirred in SOCl2 (1 mL) at 60°C for 1 h, then was 
concentrated.  Anhydrous DCM (5 mL), compound 46 (192 mg, 0.654 mmol), and 
pyridine (80.0 mL, 0.981 mmol) were added and the reaction was stirred at R.T. for 18 h 
(under Ar).  Flash chromatographic purification (hexanes:EtOAc gradient), followed by 
preparatory RP-HPLC purification, afforded 32 as an off-white solid (87.3 mg, 31% 
yield).  1H-NMR (300 MHz, d6-DMSO) δ 10.62 (s, 1H), 8.26 (d, J = 2.0 Hz, 1H), 7.91-7.98 
(m, 2H), 7.82-7.90 (m, 2H), 7.63 (dd, J = 7.5, 1.7 Hz, 1H), 7.51-7.57 (m, 1H), 7.43-7.49 
(m, 1H), 7.31-7.38 (m, 1H), 7.21 (d, J = 8.3 Hz, 1H), 7.05-7.14 (m, 1H), 3.89 (s, 3H); MS 
(ESI) C21H14ClN2O2S2 [MH]+ m/z expected = 427.0, observed = 427.0; HPLC-1 = 99%; 
HPLC-2 = 97%. 
 .......................................................................................................................................... 
33: N-(4-(Benzo[d]thiazol-2-ylthio)phenyl)-3,5-dibromo-2-
methoxybenzamide.  Compound 48 (172 mg, 0.555 mmol) 
was stirred in anhydrous DCM (5 mL) with DCC (120 mg, 0.579 mmol) and DMAP (9.0 
mg, 0.074 mmol) at R.T. for 1 h (under Ar).  Compound 47 (121 mg, 0.469 mmol) was 
then added and the reaction was stirred for an additional 18 h.  Flash chromatgraphic 
purification (hexanes:EtOAc gradient) afforded 33 as a white solid (221 mg, 86% yield).  
1H-NMR (300 MHz, d6-DMSO) δ 10.85 (s, 1H), 8.08 (d, J = 2.3 Hz, 1H), 7.89-7.96 (m, 
3H), 7.79-7.86 (m, 4H), 7.45 (td, J = 7.7, 1.3 Hz, 1H), 7.30-7.37 (m, 1H), 3.84 (s, 3H); 
47 
MS (ESI) C21H13Br2N2O2S2 [M-H]- m/z expected = 546.9, observed = 456.7; HPLC-1 = 
97%; HPLC-2 = 97%. 
 .......................................................................................................................................... 
34: N-(4-(Benzo[d]thiazol-2-ylthio)phenyl)-3-bromo-2-
methoxybenzamide.  3-Bromo-2-methoxybenzoic acid (160 
mg, 0.692 mmol) was stirred in anhydrous DCM (5 mL) with DCC (150 mg, 0.727 mmol) 
and DMAP (10.0 mg, 0.0819 mmol) at R.T. for 1 h (under Ar).  Compound 47 (150 mg, 
0.580 mmol) was then added and the reaction was stirred for an additional 18 h.  Flash 
chromatgraphic purification (hexanes:EtOAc gradient) afforded 34 as a white solid (184 
mg, 67% yield).  1H-NMR (300 MHz, d6-DMSO) δ 10.78 (s, 1H), 7.91-7.97 (m, 3H), 7.78-
7.86 (m, 4H), 7.59 (dd, J = 7.6, 1.5 Hz, 1H), 7.45 (td, J = 7.7, 1.2 Hz, 1H), 7.30-7.37 (m, 
1H), 7.19-7.26 (m, 1H), 3.84 (s, 3H); MS (ESI) C21H14BrN2O2S2 [M-H]- m/z expected = 
469.0, observed = 468.8; HPLC-1 = >99%; HPLC-2 = >99%. 
 .......................................................................................................................................... 
35: N-(4-(Benzo[d]thiazol-2-ylthio)phenyl)-5-bromo-2-
methoxybenzamide.  Compound 49 (154 mg, 0.667 mmol) 
was stirred in SOCl2 (1 mL) at 60°C for 1 h, then was concentrated.  Anhydrous DCM (5 
mL), compound 47 (117 g, 0.453 mmol), and pyridine (55.0 mL, 0.674 mmol) were added 
and the reaction was stirred at R.T. for 18 h (under Ar).  Flash chromatographic 
purification (hexanes:EtOAc gradient) afforded 35 as an off-white solid (199 mg, 93% 
yield).  1H-NMR (300 MHz, d6-DMSO) δ 10.56 (s, 1H), 7.90-7.97 (m, 3H), 7.77-7.86 (m, 
3H), 7.66-7.74 (m, 2H), 7.42-7.48 (m, 1H), 7.30-7.37 (m, 1H), 7.18 (d, J = 8.8 Hz, 1H), 
3.89 (s, 3H); MS (ESI) C21H14BrN2O2S2 [M-H]- m/z expected = 469.0, observed = 468.8; 
HPLC-1 = >99%; HPLC-2 = >99%. 
48 
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36: N-(4-(Benzo[d]thiazol-2-ylthio)phenyl)-2-
methoxybenzamide.  2-Methoxybenzoic acid (150 mg, 0.988 
mmol) was stirred in SOCl2 (1 mL) at 60°C for 1 h, then was concentrated.  Anhydrous 
DCM (5 mL), compound 47 (170 mg, 0.657 mmol), and pyridine (81.0 mL, 0.993 mmol) 
were added and the reaction was stirred at R.T. for 18 h (under Ar).  Flash 
chromatographic purification (hexanes:EtOAc gradient), followed by preparatory RP-
HPLC purification, afforded 36 as a white solid (81.3 mg, 32% yield).  1H-NMR (300 
MHz, d6-DMSO) δ 10.48 (s, 1H), 7.90-7.99 (m, 3H), 7.76-7.86 (m, 3H), 7.62 (dd, J = 7.5, 
1.6 Hz, 1H), 7.49-7.57 (m, 1H), 7.42-7.49(m, 1H), 7.29-7.37 (m, 1H), 7.20 (d, J = 8.3 Hz, 
1H), 7.08 (t, J = 7.4 Hz, 1H), 3.91 (s, 3H); MS (ESI) C21H15N2O2S2 [M-H]- m/z expected = 
391.1, observed = 390.9; HPLC-1 = >99%; HPLC-2 = >99%. 
 .......................................................................................................................................... 
37: 3,5-Dibromo-N-(3-chlorophenyl)-2-methoxybenzamide.  
Compound 48 (259 mg, 0.835 mmol) was stirred in SOCl2 (2 mL) at 
60°C for 1 h, then was concentrated.  Anhydrous DCM (5 mL), 3-
chloroaniline (73.0 mL, 0.694 mmol), and pyridine (74.0 mL, 0.907 mol) were added and 
the reaction was stirred at R.T. for 18 h (under Ar).  Flash chromatographic purification 
(hexanes:EtOAc gradient) afforded 37 as an off-white solid (280 mg, 80% yield). 1H-
NMR (300 MHz, d6-DMSO) δ 10.68 (s, 1H), 8.06 (d, J = 2.4 Hz, 1H), 7.90 (t, J = 2.0 Hz, 
1H), 7.77 (d, J = 2.4 Hz, 1H), 7.57 (d, J = 8.2 Hz, 1H), 7.39 (t, J = 8.1 Hz, 1H), 7.16-7.22 
(m, 1H), 3.81 (s, 3H); MS (ESI) C14H9Br2ClNO2 [M-H]- m/z expected = 415.9, observed = 
415.7; HPLC-1 = 99%; HPLC-2 = 97%. 
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38: 3,5-Dibromo-N-(3-chlorophenyl)-2-methoxybenzamide.  3-
Bromo-2-methoxybenzoic acid (382 mg, 1.65 mmol) was stirred in 
SOCl2 (3 mL) at 60°C for 1 h, then was concentrated.  Anhydrous DCM (5 mL), 3-
chloroaniline (0.15 mL, 1.4 mmol), and pyridine (0.13 mL, 1.6 mmol) were added and the 
reaction was stirred at R.T. for 18 h (under Ar).  Flash chromatographic purification 
(hexanes:EtOAc gradient) afforded 38 as a white solid (303 mg, 63% yield).  1H-NMR 
(300 MHz, d6-DMSO) δ 10.60 (s, 1H), 7.91-7.95 (m, 1H), 7.80 (dd, J = 8.0, 1.6 Hz, 1H), 
7.57-7.62 (m, 1H), 7.55 (dd, J = 7.6, 1.6 Hz, 1H), 7.38 (t, J = 8.1 Hz, 1H), 7.15-7.23 (m, 
2H), 3.81 (s, 3H); MS (ESI) C14H12BrClNO2 [MH]+ m/z expected = 342.0, observed = 
342.1; HPLC-1 = >99%; HPLC-2 = >99%. 
 .......................................................................................................................................... 
39: 5-Bromo-N-(3-chlorophenyl)-2-methoxybenzamide.  Compound 49 
(327 mg, 1.42 mmol) was stirred in SOCl2 (3 mL) at 60°C for 1 h, then 
was concentrated.  Anhydrous DCM (5 mL), 3-chloroaniline (0.12 mL, 1.1 
mmol), and pyridine (0.12 mL, 1.5 mmol) were added and the reaction was stirred at 
R.T. for 18 h (under Ar).  Flash chromatographic purification (hexanes:EtOAc gradient) 
afforded 39 as an off-white solid (345 mg, 89% yield).  1H-NMR (300 MHz, d6-DMSO) δ 
10.37 (s, 1H), 7.91 (t, J = 2.0 Hz, 1H), 7.65-7.72 (m, 2H), 7.57-7.63 (m, 1H), 7.37 (t, J = 
8.1 Hz, 1H), 7.13-7.19 (m, 2H), 3.87 (s, 3H(; MS (ESI) C14H12BrClNO2 [MH]+ m/z 
expected = 342.0, observed = 342.1; HPLC-1 = >99%; HPLC-2 = >99%. 
 .......................................................................................................................................... 
40: N-(3-Chlorophenyl)-2-methoxybenzamide.  2-Methoxybenzoic acid 
(189 mg, 1.24 mmol) was stirred in SOCl2 (2 mL) at 60°C for 1 h, then was 
concentrated.  Anhydrous DCM (5 mL), 3-chloroaniline (0.11 mL, 1.0 mmol), and 
pyridine (0.10 mL, 1.2 mmol) were added and the reaction was stirred at R.T. for 18 h 
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(under Ar).  Flash chromatographic purification (hexanes:EtOAc gradient), followed by 
preparatory RP-HPLC purification, afforded 40 as a white solid (81.3 mg, 32% yield).  
1H-NMR (300 MHz, d6-DMSO) δ 10.30 (s, 1H), 7.95 (t, J = 2.0 Hz, 1H), 7.58-7.66 (m, 
2H), 7.47-7.55 (m, 1H), 7.36 (t, J = 8.1 Hz, 1H), 7.12-7.21 (m, 2H), 7.07 (td, J = 7.5, 0.9 
Hz, 1H), 3.89 (s, 3H); MS (ESI) C14H13ClNO2 [MH]+ m/z expected = 262.1, observed = 
262.1; HPLC-1 = >99%; HPLC-2 = >99%. 
 .......................................................................................................................................... 
41: 3,5-Dibromo-2-methoxy-N-phenylbenzamide.  Compound 48 
(274 mg, 0.885 mmol) was stirred in SOCl2 (2 mL) at 60°C for 1 h, then 
was concentrated.  Anhydrous DCM (5 mL), aniline (69.0 mL, 0.756 mmol), and pyridine 
(58.0 mL, 0.0.711 mol) were added and the reaction was stirred at R.T. for 18 h (under 
Ar).  Flash chromatographic purification (hexanes:EtOAc gradient) afforded 41 as an off-
white solid (258 mg, 80% yield). 1H-NMR (300 MHz, d6-DMSO) δ 10.49 (s, 1H), 8.04 (d, 
J = 2.3 Hz, 1H), 7.75 (d, J = 2.4 Hz, 1H), 7.67-7.73 (m, 2H), 7.36 (t, J = 7.9 Hz, 2H), 
7.08-7.16 (m, 1H), 3.81 (s, 3H); MS (ESI) C14H10Br2NO2 [M-H]- m/z expected = 381.9, 
observed = 381.7; HPLC-1 = >99%; HPLC-2 = >99%. 
 .......................................................................................................................................... 
42: 3-Bromo-2-methoxy-N-phenylbenzamide.  3-Bromo-2-
methoxybenzoic acid (356 mg, 1.54 mmol) was stirred in SOCl2 (3 mL) 
at 60°C for 1 h, then was concentrated.  Anhydrous DCM (5 mL), aniline (0.12 mL, 1.3 
mmol), and pyridine (0.13 mL, 1.6 mmol) were added and the reaction was stirred at 
R.T. for 18 h (under Ar).  Flash chromatographic purification (hexanes:EtOAc gradient) 
afforded 42 as a white solid (315 mg, 79% yield).  1H-NMR (300 MHz, d6-DMSO) δ 10.40 
(s, 1H), 7.78 (dd, J = 8.0, 1.6 Hz, 1H), 7.69-7.75 (m, 2H), 7.54 (dd, J = 7.6, 1.6 Hz, 1H), 
7.32-7.38 (m, 2H), 7.19 (t, J = 7.8 Hz, 1H), 7.07-7.14 (m, 1H), 3.82 (s, 3H); MS (ESI) 
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C14H13BrNO2 [MH]+ m/z expected = 306.0, observed = 306.1; HPLC-1 = >99%; HPLC-2 
= >99%. 
 .......................................................................................................................................... 
43: 5-Bromo-2-methoxy-N-phenylbenzamide.  Compound 49 (302 mg, 
1.31 mmol) was stirred in SOCl2 (3 mL) at 60°C for 1 h, then was 
concentrated.  Anhydrous DCM (5 mL), aniline (0.10 mL, 1.1 mmol), and pyridine (0.11 
mL, 1.3 mmol) were added and the reaction was stirred at R.T. for 18 h (under Ar).  
Flash chromatographic purification (hexanes:EtOAc gradient) afforded 43 as a white 
solid (250 mg, 74% yield).  1H-NMR (300 MHz, d6-DMSO) δ 10.20 (s, 1H), 7.63-7.73 (m, 
4H), 7.31-7.37 (m, 2H), 7.15 (d, J = 8.8 Hz, 1H), 7.06-7.13 (m, 1H), 3.87 (s, 3H); MS 
(ESI) C14H13BrNO2 [MH]+ m/z expected = 306.0, observed = 306.1; HPLC-1 = >99%; 
HPLC-2 = >99%. 
 .......................................................................................................................................... 
44: 2-Methoxy-N-phenylbenzamide.  2-Methoxybenzoic acid (178 mg, 
1.17 mmol) was stirred in SOCl2 (2 mL) at 60°C for 1 h, then was 
concentrated.  Anhydrous DCM (5 mL), aniline (0.10 mL, 1.1 mmol), and pyridine (0.10 
mL, 1.2 mmol) were added and the reaction was stirred at R.T. for 18 h (under Ar).  
Flash chromatographic purification (hexanes:EtOAc gradient) afforded 44 as a white 
solid (235 mg, 94% yield).  1H-NMR (300 MHz, d6-DMSO) δ 10.12 (s, 1H), 7.71-7.77 (m, 
2H), 7.62 (dd, J = 7.5, 1.8 Hz, 1H), 7.46-7.54 (m, 1H), 7.30-7.37 (m, 2H), 7.18 (d, J = 8.1 
Hz, 1H), 7.04-7.12 (m, 2H), 3.89 (s, 3H); MS (ESI) C14H14NO2 [MH]+ m/z expected = 
228.1, observed = 228.1; HPLC-1 = >99%; HPLC-2 = >99%. 
 .......................................................................................................................................... 
46: 4-(Benzo[d]thiazol-2-ylthio)-3-chloroaniline.  Tin powder (5.64 g, 
47.5 mmol) was added slowly to a stirring mixture of 45 in a 1:10 mixture 
of HCl:AcOH (15 mL).  The reaction was allowed to stir at R.T. for 2 days, then diluted 
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with EtOAc and H2O, neutralized with NaHCO3, and filtered. The filtrate was extracted 
with EtOAc and the organics dried over Na2SO4, filtered, and concentrated.  The crude 
product was then chromatographed over silica (hexanes:EtOAc gradient) and 
concentrated.  The residue was diluted in a 4:1 mixture of hexanes:DCM and the 
precipitate was filtered and dried to afford 46 as a yellow powder (3.73 g, 81% yield). 1H-
NMR (300 MHz, d6-DMSO) δ 7.87-7.96 (m, 1H), 7.80 (d, J = 8.1 Hz, 1H), 7.53 (d, J = 8.5 
Hz, 1H), 7.43 (td, J = 7.7, 1.3 Hz, 1H), 7.26-7.34 (m, 1H), 6.87 (d, J = 2.4 Hz, 1H), 6.64 
(dd, J = 8.5, 2.4 Hz, 1H), 6.18 (s, 2H); MS (ESI) C13H10ClN2S2 [MH]+ m/z expected = 
293.0, observed = 293.0; HPLC-1 = 98%. 
 .......................................................................................................................................... 
47: 4-(Benzo[d]thiazol-2-ylthio)aniline.  2-Chlorobenzothiazole (2.00 
g, 11.8 mmol), 4-aminothiophenol (1.70 g, 13.6 mmol), and potassium 
carbonate (3.24 g, 23.4 mmol) were stirred together in EtOH (15 mL) for 18 h.  The 
reaction was then diluted with water and the precipitate was filtered, rinsed with water, 
and collected.  Flash chromatographic purification (hexanes:EtOAc gradient) afforded 47 
as an off-white solid (2.71 g, 89% yield).  1H-NMR (300 MHz, d6-DMSO) δ 7.85-7.91 (m, 
1H), 7.78 (d, J = 7.7 Hz, 1H), 7.37-7.45 (m, 3H), 7.25-7.34 (m, 1H), 6.66-6.73 (m, 2H), 
5.84 (s, 1H); MS (ESI) C13H11N2S2 [MH]+ m/z expected = 259.0, observed = 259.0; 
HPLC-1 = >99%. 
 .......................................................................................................................................... 
48: 3,5-Dibromo-2-methoxybenzoic acid.  Iodomethane (6.30 mL, 101 
mmol), 3,5-dibromosalicylic acid (10.0 g, 33.7 mmol), and K2CO3 (14.0 g, 
101 mmol) were stirred at R.T. overnight, then at 80°C for 4 h.  The 
reaction was diluted into water and extracted into DCM.  The organics were dried over 
Na2SO4, filtered, and concentrated.  The intermediate ester was then stirred overnight 
with LiOH•H2O (5.70 g, 136 mmol) in a 3:1:1 mixture of THF:MeOH:H2O (35 mL).  The 
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reaction was diluted with water and acidified with HCl.  The precipitate was filtered, 
washed with water, and dried to afford 48 as a white solid (9.85 g, 94% yield).  1H-NMR 
(300 MHz, d6-DMSO) δ 13.56 (br s, 1H), 8.09 (d, J = 2.5 Hz, 1H), 7.83 (d, J = 2.5 Hz, 
1H), 3.81 (s, 3H); MS (ESI) C8H5Br2O3 [M-H]- m/z expected = 308.9, observed = 309.1; 
HPLC-1 = >99%. 
 .......................................................................................................................................... 
49: 5-Bromo-2-methoxybenzoic acid.  5-Bromosalicylic acid (10.0 g, 46.1 
mmol), iodomethane (8.60 mL, 138 mmol), and K2CO3 (19.0 g, 137 mmol) 
were stirred at R.T. overnight, then at 80°C for 4 h.  The reaction was 
diluted into water and the precipitate was filtered, rinsed with water, and dried.  The 
intermediate ester was then stirred overnight with LiOH•H2O (7.70 g, 184 mmol) in a 
3:1:1 mixture of THF:MeOH:H2O (45 mL).  The reaction was diluted with water and 
acidified with HCl.  The precipitate was filtered, washed with water, and dried to afford 
49 as a white solid (8.70 g, 82% yield).  1H-NMR (300 MHz, d6-DMSO) δ 12.98 (br s, 
1H), 7.72 (d, J = 2.6 Hz, 1H), 7.66 (dd, J = 8.8, 2.6 Hz, 1H), 7.10 (d, J = 8.9 Hz, 1H), 
3.81 (s, 3H); MS (ESI) C8H6BrO3 [M-H]- m/z expected = 229.0, observed = 229.0; HPLC-
1 = 98%. 
 .......................................................................................................................................... 
GroEL and GroES Protein Expression and Purification  
E. coli GroEL was expressed from a trc-promoted and Amp(+) resistance marker 
plasmid in DH5α E. coli cells. E. coli GroES was expressed from a T7-promoted and 
Amp(+) resistance marker plasmid in E. coli BL21 (DE3) cells.  Transformed colonies 
were plated onto Ampicillin treated LB agar and incubated for 24 h at 37°C. Cells were 
grown at 37°C in Ampicillin treated LB medium until an OD600 of 0.5 was reached, then 
were induced with 0.5 mM IPTG and continued to grow for 2-3 h at 37°C. The cultures 
were centrifuged at 14,000 rpm, and the cell pellets re-suspended in Buffer A (50 mM 
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sodium acetate, pH 4.5, and 0.5 mM EDTA), supplemented with EDTA-free complete 
protease inhibitor cocktail (Roche), 100 µg/ml lysozyme, 10 µL (1000 u/ml) DNAase, and 
lysed by sonication.  Clarified cell lysates were loaded on a cation exchange column (SP 
Sepharose fast flow resin, GE) and eluted with linear NaCl gradient with Buffer B 
(sodium acetate, pH 4.5, 0.5 mM EDTA, and 1 M NaCl).  Fractions containing protein on 
the absorption spectrum were then quantified on an SDS PAGE gel, collected, and spin 
concentrated using 10 kD filter canonicals. Once concentrated to ~25μM, proteins were 
dialyzed in size-exclusion buffer (50 mM Tris-HCl, pH 7.4, and 300 mM NaCl) with 10 
kDa SnakeSkin™ dialysis tubing (Thermo Scientific) for at least 12 hours. Proteins were 
then further purified using a Superdex 200 (HiLoad 26/600, GE) size-exclusion column 
with size-exclusion buffer, and eluted off into fractions with filtered H2O. Fractions were 
then quantified by molecular weight using SDS PAGE, then spin concentrated (~150μM 
GroES, ~30μM GroEL). The concentration of protein was determined by Coomassie 
Protein Assay Kit (Thermo Scientific).  
Human HSP60 and HSP10 Protein Expression and Purification  
Human HSP60 purification:   
Human mitochondrial HSP60 (mtHSP60) was expressed from a T7-promoted 
plasmid with an AMP and Chloramphenicol resistance marker in Rosetta™ 2 (DE3) 
pLysS E. coli using a previously reported plasmid (Abdeen 2016). For human HSP60 
purification, pET21-mtHSP60 with N-terminal octa-Histidine tag was transformed into 
Rosetta™ 2 (DE3) pLysS E. coli cells for over-expression.  Cells were grown at 37°C in 
LB / Ampicillin / Chloramphenicol medium until an OD600 of 0.5 was reached at 37°C, 
then induced with 0.5 mM IPTG and continued to grow for 2-3 h at 25°C.  After 
centrifuging at 14,000 rpm, the cell pellet was suspended in a 50 mL lysis buffer 
composed of 100 mM Tris-HCl (pH 7.7), 10 mM MgSO4, 1 mM β-ME, 5% glycerol, 0.1% 
Triton X-100, 1500 Units DNase, and 100 µl of 50 mg/ml lysozyme. Cells were 
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homogenized by passing through a microfluidizer using a buffer containing 10 mM Tris-
HCl (pH 7.7), 5% glycerol, and 0.1% Triton X-100.  
1st Nickel column purification and proteolytic removal of His-tag:   
Cell lysate was supplemented with 10 mM imidazole, passed through a 0.2 μm 
filter (Millipore), and loaded onto a nickel-agarose resin column that was equilibrated 
with 20 mM Tris-HCl (pH 7.7), 5% glycerol, 200 mM NaCl, and 10 mM imidazole. Bound 
mtHSP60 was eluted with 500 mM Imidazole. Fractions that were enriched with the His-
tagged mtHSP60 were collected, concentrated, dialyzed in 10 kDa SnakeSkin™ dialysis 
tubing (Thermo Scientific) at room temperature for 2 hours in 4 L of 20 mM Tris-HCl (pH 
7.7), 200 mM NaCl, and 5% glycerol to remove imidazole. Proteolytic removal of the His-
tag was next performed by addition of His-tagged TEV protease to the purified His-
tagged mtHSP60 at a 1:10 (w:w) ratio, while dialyzing over night at 4°C in buffer 
containing 20 mM Tris-HCl (pH 7.7), 200 mM NaCl, and 5% glycerol. 
2nd Nickel column purification:  
The protein sample was loaded onto a second nickel-agarose resin column that 
was equilibrated with 20 mM Tris-HCl (pH 7.7), 5% glycerol, 10 mM NaCl, and 10 mM 
imidazole. The unbound fractions enriched with His-tag cleaved mtHSP60 were 
collected by raising Imidazole concentration. In this column, processed mtHSP60 can be 
separated from undigested His-tagged mtHSP60 as well as the His-tagged TEV 
protease.  Anion-exchange purification was then performed on the same day. 
Anion-exchange purification of processed mtHSP60:  
Protein sample was loaded onto an anion-exchange column (SP Sepharose fast 
flow resin, GE) that was equilibrated with 20 mM Tris-HCl (pH 7.7) and 5% glycerol. 
Bound proteins were eluted from the column with a linear gradient of 100-400 mM NaCl. 
Fractions enriched with mtHSP60 were collected, concentrated and dialyzed in storage 
buffer (20 mM Tris-HCl (pH 7.7), 300 mM NaCl, 5% glycerol, and 10 mM MgCl2) using 
56 
10 kDa SnakeSkin™ dialysis tubing (Thermo Scientific).Protein concentration was 
determined using a Coomassie Protein Assay Kit (Thermo Scientific).  Protein can be 
stored at 4°C in storage buffer for two weeks (freeze-thaw storage is not recommended).  
Human HSP10 purification:  
For human HSP10 purification, pET30-HSP10 with a Kan and Chloramphenicol 
resistance marker was transformed into Rosetta™ 2 (DE3) E. coli cells for over-
expression.  Cells were grown at 37°C in LB / Kanamycin / Chloramphenicol medium 
until an OD600 of 0.5 was reached, then induced with 0.5 mM IPTG and continued to 
grow for 2-3 h at 37°C.  The culture was centrifuged at 14,000 rpm, and the cell pellet 
was re-suspended in Buffer A (50 mM sodium acetate (pH 4.5) and 0.5 mM EDTA) 
supplemented with EDTA-free complete protease inhibitor cocktail (Roche), 100 µg/ml 
lysozyme, 10 µL (1000 u/ml) DNAase, and lysed by sonication.  Clarified cell lysate was 
loaded on a cation-exchange column (SP Sepharose fast flow resin, GE) and eluted with 
a linear NaCl gradient of Buffer A to Buffer B (sodium acetate (pH 4.5), 0.5 mM EDTA, 
and 1 M NaCl).  Fractions containing HSP10 were concentrated, dialyzed with storage 
buffer (50 mM Tris-HCl (pH 7.4) and 300 mM NaCl) using 10 kDa SnakeSkin™ dialysis 
tubing (Thermo Scientific), and re-purified using a Superdex 200 column size-exclusion 
column (HiLoad 26/600, GE) and eluting with storage buffer.  Protein concentration was 
determined using a Coomassie Protein Assay Kit (Thermo Scientific).  Protein was 
stored at 4°C in 50 mM Tris-HCl (pH 7.4), 300 mM NaCl, and 1 mM DTT. 
Denatured Malate Dehydrogenase Refolding Assay  
Reagent preparation:   
For these assays, four primary reagent stocks were prepared: 1) 
GroEL/ESdMDH or HSP60/10-dMDH binary complex stock; 2) ATP initiation stock; 3) 
EDTA quench stock; 4) MDH enzymatic assay stock.  Denatured MDH (dMDH) was 
prepared by 2-fold dilution of MDH (5 mg/ml, soluble pig heart MDH from Roche, product 
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#10127248001) with denaturant buffer (7 M guanidine-HCl, 200 mM Tris (pH 7.4), and 
50 mM DTT).  MDH was completely denatured by mixing with denaturant buffer then 
incubating at room temperature for 40 min.  The binary complex solutions were prepared 
by adding the dMDH stock to a solution containing GroEL (or HSP60) and GroES (or 
HSP10) in folding buffer (50 mM Tris-HCl (pH 7.4), 50 mM KCl, 10 mM MgCl2, and 1 mM 
DTT). The binary complex stocks were prepared prior to use and had final protein 
concentrations of 83.3 nM GroEL (MW 800 kDa) or HSP60 (MW 400 kDa), 100 nM 
GroES or HSP10 (MW 70 kDa), and 20 nM dMDH.  For the ATP initiation stock, solid 
ATP was diluted into folding buffer to a final concentration of 2.5 mM.  Quench solution 
contained 600 mM EDTA (pH 8.0).  The MDH enzymatic assay stock consisted of 20 
mM sodium mesoxalate and 2.4 mM NADH in reaction buffer (50 mM Tris-HCl (pH 7.4), 
50 mM KCl, and 1 mM DTT). 
Assay Protocol:   
First, 30 µL aliquots of the GroEL/ES-dMDH or HSP60/10-dMDH binary complex 
stocks were pipetted into clear, flat-bottom, 384-well polystyrene plates.  Next, 0.5 µL of 
the compound stocks (10 mM to 4.6 µM, 3-fold dilutions in DMSO) were added by pin-
transfer (V&P Scientific).  The chaperonin-mediated refolding cycles were initiated by 
addition of 20 µL of ATP stock (reagent concentrations during refolding cycle: 50 nM 
GroEL or HSP60, 60 nM GroES or HSP10, 12 nM dMDH, 1 mM ATP, and compounds of 
100 µM to 46 nM, 3-fold dilution series).  After incubation for 45 minutes at 37°C (time of 
quenching found from kinetics assay ran prior – see note below), the assays were 
quenched by addition of 10 µL of the EDTA stock.  Enzymatic activity of the refolded 
MDH was initiated by addition of 20 µL MDH enzymatic assay stock and followed by 
measuring the NADH absorbance in each well at 340 nm using a Molecular Devices 
SpectraMax Plus384 microplate reader (NADH absorbs at 340 nm, while NAD+ does 
not).  A340 measurements were recorded at 0.5 minutes (start point) and at successive 
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time points until the amount of NADH consumed reached ~90% in the non-inhibited, 
DMSO control wells (end point, generally between 30-60 minutes).  The differences 
between the start and end point A340 values were used to calculate the % inhibition of the 
GroEL/ES or HSP60/10 machinery by the compounds.  IC50 values for the test 
compounds were obtained by plotting the % inhibition results in GraphPad Prism 6 and 
analyzing by non-linear regression using the log(inhibitor) vs. response (variable slope) 
equation.  Results presented represent the averages of IC50 values obtained from at 
least triplicate experiments.  
Note: Time of quenching with EDTA was found from kinetics testing of purified protein 
where quenching took place over a time course of 60 min to know if the protein was 
functional, the time it took for the chaperonin system to have just completed refolding of 
~90% dMDH (quench time point during the assays).    
Denatured Rhodanese Refolding Assay  
Reagent preparation:   
For this assay, five primary reagent stocks were prepared: 1) GroEL/ES-dRho 
binary complex stock; 2) ATP initiation stock; 3) thiocyanate enzymatic assay stock; 4) 
formaldehyde quench stock; 5) ferric nitrate reporter stock.  Denatured Rhodanese 
(dRho) was prepared by 3-fold dilution of Rhodanese (Roche product #R1756, diluted to 
10 mg/mL with H2O) with denaturant buffer (12 M urea, 50 mM Tris-HCl (pH 7.4), and 10 
mM DTT) and incubated at room temperature for 30 min.  The binary complex solution 
was prepared by slowly adding the dRho stock to a stirring stock of concentrated GroEL 
in modified folding buffer (50 mM Tris-HCl (pH 7.4), 50 mM KCl, 10 mM MgCl2, 5 mM 
Na2S2O3, and 1 mM DTT).  The solution was centrifuged at 16,000 x g for 5 minutes, and 
the supernatant was collected and added to a solution of GroES in modified folding 
buffer to give final protein concentrations of 100 nM GroEL, 120 nM GroES, and 80 nM 
dRho.  The binary complex stock was prepared immediately prior to use.  For the ATP 
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initiation stock, solid ATP was diluted into modified folding buffer to a final concentration 
of 2.0 mM.  The thiocyanate enzymatic assay stock was prepared to contain 70 mM 
KH2PO4, 80 mM KCN, and 80 mM Na2S2O3 in water.  The formaldehyde quench solution 
contained 30% formaldehyde in water.  The ferric nitrate reporter stock contained 8.5% 
w/v Fe(NO3)3 and 11.3% v/v HNO3 in water.  
Assay Protocol:   
First, 10 µL aliquots of the GroEL/ES-dRho complex stock were dispensed into 
clear, flat-bottom, 384-well polystyrene plates.  Next, 0.5 µL of the compound stocks (10 
mM to 4.6 µM, 3-fold dilutions in DMSO) were added by pin-transfer.  The chaperonin-
mediated refolding cycle was initiated by addition of 10 µL of ATP stock (reagent 
concentrations during refolding cycle: 50 nM GroEL, 60 nM GroES, 40 nM dRho, 1 mM 
ATP, and compounds of 250 µM to 114 nM, 3-fold dilution series).  After incubating for 
60 minutes at 37°C for the refolding cycle, 30 µL of the thiocyanate enzymatic assay 
stock was added to initiate the enzymatic reporter reaction of the refolded rhodanese.  
After incubating for 60 min at R.T., the reporter reaction was quenched by adding 10 µL 
of the formaldehyde quench stock, and then 40 µL of the ferric nitrate reporter stock was 
added to quantify the amount of thiocyanate produced, which is proportional to the 
amount of dRho refolded by GroEL/ES.  After incubating at R.T. for 15 min, the 
absorbance by Fe(SCN)3 was measured at 460 nm using a Molecular Devices 
SpectraMax Plus384 microplate reader.  A second set of baseline control plates were 
prepared analogously, but without binary solution, to correct for possible interference 
from compound absorbance or turbidity.  IC50 values for the test compounds were 
obtained by plotting the A460 results in GraphPad Prism 6 and analyzing by non-linear 
regression using the log(inhibitor) vs. response (variable slope) equation.  Results 
presented represent the averages of IC50 values obtained from at least 4 replicates of 
experiments. 
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Native Malate Dehydrogenase and Native Rhodanese Activity Counter-screens  
Reagent Preparations & Assay Protocol:   
Reagents were identical to those used in the GroEL/ES-dMDH and GroEL/ES-
dRho refolding assays described above; however, the assay protocols differed in the 
sequence of compound addition to the wells.  For the native MDH counter-screen, 
compounds were pin-transferred after the EDTA quenching step, but prior to the addition 
of the enzymatic reporter reagents.  For the native rhodanese counter-screen, 
compounds were added immediately prior to addition of the enzymatic reporter reagents.  
Thus, the refolding reactions could proceed in the absence of test compounds (providing 
maximal MDH and Rho refolding), but the enzymatic activity of the refolded reporter 
enzymes (MDH and Rho) was monitored in the presence of test compounds.  The 
inhibitor concentration ranges were 83.3 µM to 38 nM (3-fold dilutions) for the MDH 
enzymatic reporter reaction, and 100 µM to 46 nM (3-fold dilutions) for the Rho 
enzymatic reporter reaction.  Results presented represent the averages of IC50 values 
obtained from at least 4 replicates of experiments. 
Bacterial Proliferation Assays 
Stock cell cultures used and storage: 
All evaluated bacterial cultures are listed below with manufacturer name(s) and 
lot #s: Enterococcus faecium cells-(Orla-Jensen) Schleifer and Kilpper-Balz strain NCTC 
7171 (ATCC 19434). Staphylococcus aureus cells -Rosenbranch strain Seattle 1945 
(ATCC 25923). Methicillin-resistant S. aureus (MRSA)-Rosenbach strain HPV107 
(ATCC BAA-44). Klebsiella Pneumonia cells- (Schroeter) Trevisan strain NCTC 9633 
(ATCC 13883). Acinetobacter baumanii cells- Bouvet and Grimont strain 2208 (ATCC 
19606). Pseudomonas aeruginosa cells- (Schroeter) Migula strain NCTC 10332 (ATCC 
10145). Enterobacter cloacae cells- E. cloacae, subsp. cloacae (Jordan) Hormaeche 
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and Edwards strain CDC 442-68 (ATCC 13047). All bacterial cell stocks were stored at -
80°C.  
 
General Assay Protocol: 
Stock bacterial cultures were streaked onto BHI (Brain-heart infusion media, 
Becton, Dickinson, and Company) agar plates and grown overnight at 37°C.  Fresh 
aliquots of broth were inoculated with single bacterial colonies and the cultures were 
grown overnight at 37°C with shaking (240 rpm) in BHI media supplemented with MgCl2 
and CaCl2 to a final concentration of 2.5(Mg) and 25(Ca)mg/mL. The following morning, 
the overnight cultures were sub-cultured (1:5 dilution) into fresh aliquots of media and 
grown at 37°C for 1-2 hours with shaking.  After 2 h, cultures were diluted into fresh 
media to achieve final OD600 readings of 0.017.  Aliquots of these diluted cultures (30 µL) 
were added to clear, flat-bottom, 384-well polystyrene plates that were stamped with 0.5 
µL of test compounds in 20 µL media.  The inhibitor concentration range during the 
proliferation assay was 100 µM to 46 nM (3-fold dilution series).  Plates were sealed with 
"Breathe Easy" oxygen permeable membranes (Diversified Biotech) and left to incubate 
at 37°C without shaking (stagnant assay).  OD600 readings were taken at either 6-8 h (S. 
aureus, Klebsiella, E. cloacae, P. aeruginosa, and MRSA) or 24 h (E. faecium and A. 
baumanii).  A second set of baseline control plates were prepared analogously, but 
without any bacteria added, to correct for possible compound absorbance and/or 
precipitation. Plates were then read at 600 nm using a Molecular Devices SpectraMax 
Plus384 microplate reader.  EC50 values for the test compounds were obtained by 
plotting the OD600 results in GraphPad Prism 6 and analyzing by non-linear regression 
using the log(inhibitor) vs. response (variable slope) equation.  Results presented 
represent the averages of EC50 values obtained from at least 4 replicates of 
experiments. 
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Human Cell Cytotoxicity Assay Using HEK 293 and THLE-3 Cell Lines 
HEK 293 kidney cells (ATCC #CRL-1573) were maintained in MEM medium 
(Corning Cellgro, 10-009 CV) supplemented with 10% FBS (Sigma, F2242).  THLE-3 
liver cells (ATCC #CRL-11233) were maintained in Clonetics BEBM medium (Lonza, 
CC-3171) supplemented with the BEGM bullet kit (Lonza, CC-3170) and 10% FBS.  All 
assays were carried out in clear, flat-bottom, 384-well polystyrene plates (BRAND cell 
culture grade plates, 781980).  Briefly, cells at 80% confluence were harvested and 
diluted in growth medium, then 50 µL of the HEK 293 cells (15,000 cells/well) or THLE-3 
cells (5,000 cells/well) were plated and incubated at 37°C with 5% CO2 for 24 h.  
Compound stocks (1 µL of 10 mM to 4.6 µM, 3-fold dilutions in DMSO) were added by 
pin-transfer and the plates were incubated for an additional 48 h at 37°C with 5% CO2.  
Alamar Blue reporter reagents were then added to a final concentration of 10% (6 µL in 
60 µL of treated cells).  The plates were incubated for 24 h, then sample fluorescence 
(535 nm excitation, 590 nm emission) was read using a Molecular Devices FlexStation II 
plate reader.  Cell viability was calculated as per vendor instructions.  CC50 values for 
the test compounds were obtained by plotting the % Alamar Blue reduction results in 
GraphPad Prism 6 and analyzing by non-linear regression using the log(inhibitor) vs. 
response (variable slope) equation.  Results presented represent the averages of CC50 
values obtained from at least 4 replicates of experiments. 
MRSA Gain-of-Resistance Assay  
To identify potential resistance toward the parent scaffold (1) and analog 11, a 
liquid culture serial passage assay for a period of 12 consecutive days was carried out 
alongside control compounds vancomycin and “28R” with Methicillin-resistant 
Staphylococcus aureus (MRSA ATCC BAA-44), as described elsewhere (Kim  2014). In 
brief, MRSA (ATCC BAA-44) bacteria were streaked onto a Tryptic Soy Broth (TSB) 
agar plate and grown overnight at 37°C.  A fresh aliquot of TSB was inoculated with a 
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single bacterial colony and the cultures were grown overnight at 37°C with shaking (250 
rpm).  The overnight culture was then sub-cultured (1:5 dilution) into a fresh aliquot of 
media and grown at 37°C for 1 h with shaking, then diluted into fresh media to achieve a 
final OD600 reading of 0.01. Aliquots of the diluted culture (200 µL) were dispensed into 
96 well plates along with addition of 2 µL test compounds in DMSO. The inhibitor 
concentration range during the resistance assay was 100 µM to 48.8 nM (2-fold dilution 
series).   Plates were sealed with "Breathe Easy" oxygen permeable membranes 
(Diversified Biotech) and left to incubate at 37°C without shaking (stagnant assay).  
OD600 readings were taken at the 24 h time point to monitor for bacterial growth.  A 
second set of baseline control plates were prepared analogously, but without any 
bacteria added, to correct for possible compound absorbance and/or precipitation, as 
well as plate and media baseline effects.  For inoculations on subsequent days, bacteria 
from the wells with the highest drug concentration, where the OD600  was >0.2, were 
diluted with fresh media to OD600 of 0.01 and dispensed into a new 96-well plate. Test 
compounds were added, and the bacteria propagated again as described above. This 
procedure was repeated each day for a total of 12 days to observe whether EC50 values 
would increase, indicating that bacteria were generating resistance to the test 
compound.  EC50 values for the test compounds were obtained by plotting the OD600 
results in GraphPad Prism 6 and analyzing by non-linear regression using the 
log(inhibitor) vs. response (variable slope) equation.  Results presented represent the 
averages of EC50 values obtained from at least 4 replicates of experiments. 
S. aureus Biofilm Prevention Assay  
The biofilm prevention assay was carried out with S. aureus Rosenbach (ATCC 
25923) using a quantitative crystal violet-based adherence assay on 96-well plates as 
described previously (Kwasny 2010). S. aureus (ATCC 25923) bacteria were streaked 
onto a Tryptic Soy Broth (TSB) agar plate and grown overnight at 37°C.  A fresh aliquot 
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of TSB media was inoculated with a single bacterial colony and the cultures were grown 
overnight at 37°C with shaking (250 rpm).  The overnight culture was then sub-cultured 
(1:5 dilution) into a fresh aliquot of TSB media supplemented to a final conc. of 0.5% 
glucose and grown at 37°C for 1 h with shaking, then diluted into fresh TSB media 
supplemented with 0.5% glucose to achieve a final OD600 reading of 0.01. Aliquots of the 
diluted culture (100 µL) were dispensed to 96 well polystyrene plates along with addition 
of 1 µL test compounds in DMSO. The inhibitor concentration range during the assay 
was 100 µM to 46 nM (3-fold dilution series).  A second set of baseline control plates 
were prepared analogously, but without any bacteria added, to correct for possible 
compound absorbance and/or precipitation. Plates were sealed with "Breathe Easy" 
oxygen permeable membranes (Diversified Biotech) and left to incubate at 37°C without 
shaking (stagnant assay) until the biofilm was formed.  After 24 h, the planktonic cultures 
were removed and the plates were washed gently 2-3 times with 200 μl of water. Next 
the plates were air dried and the adherent biofilms were stained with 150 μL of 2.3% 
crystal violet (2.3 % crystal violet in 20% Ethanol, Sigma Aldrich #HT90132) for 15 
minutes at room temperature. The unbound crystal violet stain was removed, then plates 
were gently washed again with running water and air dried for 10 min. Quantitative 
assessment of biofilm formation was obtained by adding 100 μL of developer solution 
(4:1:5 mixture of MeOH:AcOH:H2O) per well. Plates were then read at 595 nm using a 
Molecular Devices SpectraMax Plus384 microplate reader.  EC50 values for the test 
compounds were obtained by plotting the Absorbance 595 nm results in GraphPad 
Prism 6 and analyzing by non-linear regression using the log(inhibitor) vs. response 
(variable slope) equation.  Results presented represent the averages of EC50 values 
obtained from at least 4 replicates of experiments. 
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S. aureus Biofilm Penetration and Bactericidal Activity Assay  
The biofilm penetration and bactericidal activity assay was carried out with S. 
aureus Rosenbach (ATCC 25923) as described previously (Kwasny 2010). S. aureus 
(ATCC 25923) bacgeria were streaked onto a Tryptic Soy Broth (TSB) agar plate and 
grown overnight at 37°C.  A fresh aliquot of TSB media was inoculated with a single 
bacterial colony and the cultures were grown overnight at 37°C with shaking (250 rpm).  
The overnight culture was then sub-cultured (1:5 dilution) into a fresh aliquot of TSB 
media supplemented with 0.5% glucose and grown at 37°C for 1 h with shaking, then 
diluted into fresh TSB media supplemented with 0.5% glucose to achieve a final OD600 
reading of 0.01. Aliquots of the diluted culture (100 µL) were dispensed to 96 well 
polystyrene plates without any compounds added. A second set of baseline control 
plates were prepared analogously, but without any bacteria added, to correct for 
possible compound absorbance and/or precipitation. Plates were sealed with "Breathe 
Easy" oxygen permeable membranes (Diversified Biotech) and left to incubate at 37°C 
without shaking (stagnant assay) until biofilm was formed.  After 24 h, the planktonic 
cultures were removed and the plates were washed gently 3 times with 200 μL of sterile 
phosphate buffered saline (PBS). Then aliquots (100 µL) of fresh TSB media were 
dispensed to the plates along with addition of 1 µL of test compounds in DMSO. The 
inhibitor concentration range during the assay was 100 µM to 46 nM (3-fold dilution 
series). The plates were sealed with "Breathe Easy” membrane and incubated at 37°C 
without shaking to allow compounds to penetrate and kill bacteria in the biofilms. After 
24 h, the cultures were removed and plates were washed again gently 3 times with 200 
μL of sterile PBS. The remaining bacteria in the biofilms were allowed to recover by 
adding 100 μL of fresh TSB media per well and incubating for 24 hours at 37°C. At the 
end of this final incubation, bacterial growth was monitored by measuring the OD600 
using a Molecular Devices SpectraMax Plus384 microplate reader.  EC50 values for the 
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test compounds were obtained by plotting the OD600 results in GraphPad Prism 6 and 
analyzing by non-linear regression using the log(inhibitor) vs. response (variable slope) 
equation.  Results presented represent the averages of EC50 values obtained from at 
least 4 replicates of experiments. 
Calculating IC50, EC50, and CC50 Values  
Average IC50, EC50, and CC50 values were calculated from individual dose-
response curves in replicate assays as follows: 1) IC50 values obtained from each dose-
response curve (plotted in GraphPad Prism 6) were log-transformed and the average 
log(I/E/CC50) values and standard deviations (SD) calculated; 2) Outlier log(I/EC/C50) 
values were identified using the ROUT method in GraphPad Prism 6 (Q of 10%); and 3) 
Average IC50, EC50, and CC50 values were back-calculated from the average 
log(I/E/CC50) values.   
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APPENDIX - Tables of Log(IC50), Log(EC50), and Log(CC50) Results 
 
Table 7.  Log(IC50) results and standard deviations for compounds tested in the 
GroEL/ES-mediated dMDH and dRho folding assays, and the native MDH and Rho 
reporter counter-screens.    
 
 
 
 
 
 
 
 
 
 
Compound
# / Name
Closantel >2 0.75 ± 0.17 0.19 ± 0.10 0.33 ± 0.18
R1 R2 R3 R4 R5 Rafoxanide >2 1.1 ± 0.1 0.34 ± 0.11 0.44 ± 0.09
Cl OH Br Br 1 >2 0.93 ± 0.21 0.19 ± 0.08 0.29 ± 0.24
Cl OH Br H 2 >2 >1.8 0.58 ± 0.15 0.98 ± 0.23
Cl OH H Br 3 >2 >1.8 1.0 ± 0.4 1.6 ± 0.4
Cl OH H H 4 >2 >1.8 1.8 ± 0.3 1.6 ± 0.3
H OH Br Br 5 >2 0.92 ± 0.21 0.12 ± 0.37 0.43 ± 0.19
H OH Br H 6 >2 >1.8 1.1 ± 0.1 1.5 ± 0.2
H OH H Br 7 >2 >1.8 1.5 ± 0.1 1.6 ± 0.3
H OH H H 8 >2 >1.8 1.9 ± 0.2 1.6 ± 0.3
H Cl OH Br Br 9 >2 1.4 ± 0.2 1.7 ± 0.1 1.4 ± 0.2
H Cl OH Br H 10 >2 >1.8 >2.4 >2
H Cl OH H Br 11 >2 >1.8 >2.4 >2
H Cl OH H H 12 >2 >1.8 >2.4 >2
H H OH Br Br 13 >2 1.7 ± 0.2 >2.4 1.8 ± 0.1
H H OH Br H 14 >2 >1.8 >2.4 >2
H H OH H Br 15 >2 >1.8 >2.4 >2
H H OH H H 16 >2 >1.8 >2.4 >2
Cl H Br Br 17 >2 >1.8 >2.4 >2
Cl H Br (H) H (Br) 18 >2 >1.8 >2.4 >2
Cl H H H 19 >2 >1.8 >2.4 >2
H H Br Br 20 >2 >1.8 >2.4 >2
H H Br (H) H (Br) 21 >2 >1.8 >2.4 >2
H H H H 22 >2 >1.8 >2.4 >2
H Cl H Br Br 23 >2 >1.8 >2.4 >2
H Cl H Br (H) H (Br) 24 >2 >1.8 >2.4 >2
H Cl H H H 25 >2 >1.8 >2.4 >2
H H H Br Br 26 >2 >1.8 >2.4 >2
H H H Br (H) H (Br) 27 >2 >1.8 >2.4 >2
H H H H H 28 >2 >1.8 >2.4 >2
Cl OCH3 Br Br 29 >2 >1.8 >2.4 >2
Cl OCH3 Br H 30 >2 >1.8 >2.4 >2
Cl OCH3 H Br 31 >2 >1.8 >2.4 >2
Cl OCH3 H H 32 >2 >1.8 >2.4 >2
H OCH3 Br Br 33 >2 >1.8 >2.4 >2
H OCH3 Br H 34 >2 >1.8 >2.4 >2
H OCH3 H Br 35 >2 >1.8 >2.4 >2
H OCH3 H H 36 >2 >1.8 >2.4 >2
H Cl OCH3 Br Br 37 >2 >1.8 >2.4 >2
H Cl OCH3 Br H 38 >2 >1.8 >2.4 >2
H Cl OCH3 H Br 39 >2 >1.8 >2.4 >2
H Cl OCH3 H H 40 >2 >1.8 >2.4 >2
H H OCH3 Br Br 41 >2 >1.8 >2.4 >2
H H OCH3 Br H 42 >2 >1.8 >2.4 >2
H H OCH3 H Br 43 >2 >1.8 >2.4 >2
H H OCH3 H H 44 >2 >1.8 >2.4 >2
Compound Substituents & Substructures
Biochemical Assay IC50 (mM)
Native Rho
Reporter
Native MDH
Reporter
GroEL/ES-dRho
Refolding
GroEL/ES-dMDH
Refolding
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Table 8. Log(EC50) results and standard deviations for compounds tested in the bacterial 
proliferation assays.  
 
 
 
 
 
 
 
 
 
 
 
Closantel 0.09 ± 0.40 -0.33 ± 0.09 -0.37 ± 0.13 >2 >2 >2 >2
R1 R2 R3 R4 R5 Rafoxanide -0.003 ± 0.491 -0.49 ± 0.13 -0.53 ± 0.60 >2 1.5 ± 0.4 >2 1.6 ± 0.3
Cl OH Br Br 1 -0.29 ± 0.38 -0.44 ± 0.18 -0.34 ± 0.27 >2 1.8 ± 0.2 >2 >2
Cl OH Br H 2 1.4 ± 0.4 -0.35 ± 0.29 -0.26 ± 0.27 >2 0.46 ± 0.12 >2 >2
Cl OH H Br 3 1.2 ± 0.2 -0.93 ± 0.24 -0.09 ± 0.40 >2 >2 >2 >2
Cl OH H H 4 1.8 ± 0.5 -0.51 ± 0.31 -0.38 ± 0.30 >2 >2 >2 >2
H OH Br Br 5 -0.05 ± 0.77 -0.36 ± 0.17 -0.31 ± 0.08 >2 >2 >2 >2
H OH Br H 6 0.92 ± 1.06 -0.12 ± 0.18 -0.03 ± 0.22 >2 1.1 ± 0.2 >2 >2
H OH H Br 7 1.3 ± 0.3 -0.92 ± 0.19 -0.90 ± 0.28 >2 >2 >2 >2
H OH H H 8 1.8 ± 0.2 -0.69 ± 0.08 -0.47 ± 0.29 >2 >2 >2 >2
H Cl OH Br Br 9 1.2 ± 0.7 -0.18 ± 0.16 0.01 ± 0.24 2.0 ± 0.1 1.7 ± 0.1 >2 1.9 ± 0.2
H Cl OH Br H 10 >2 0.12 ± 0.03 0.15 ± 0.05 >2 >2 >2 >2
H Cl OH H Br 11 >2 -0.34 ± 0.02 -0.36 ± 0.02 >2 >2 >2 >2
H Cl OH H H 12 >2 0.49 ± 0.06 0.61 ± 0.07 >2 >2 >2 >2
H H OH Br Br 13 >2 0.09 ± 0.10 0.24 ± 0.11 >2 >2 >2 >2
H H OH Br H 14 >2 0.81 ± 0.05 0.94 ± 0.04 >2 >2 >2 >2
H H OH H Br 15 >2 0.44 ± 0.05 0.60 ± 0.12 1.9 ± 0.2 >2 >2 >2
H H OH H H 16 >2 1.4 ± 0.1 1.7 ± 0.10 >2 >2 >2 >2
Cl H Br Br 17 >2 >2 >2 >2 >2 >2 >2
Cl H Br (H) H (Br) 18 >2 >2 >2 >2 >2 >2 >2
Cl H H H 19 >2 1.6 ± 0.2 >2 >2 >2 >2 >2
H H Br Br 20 >2 >2 >2 >2 >2 >2 >2
H H Br (H) H (Br) 21 >2 >2 >2 >2 >2 >2 >2
H H H H 22 >2 >2 >2 >2 >2 >2 >2
H Cl H Br Br 23 >2 1.1 ± 0.1 1.1 ± 0.1 >2 >2 >2 >2
H Cl H Br (H) H (Br) 24 >2 1.7 ± 0.1 1.8 ± 0.1 >2 >2 >2 >2
H Cl H H H 25 >2 >2 >2 >2 >2 >2 >2
H H H Br Br 26 >2 >2 >2 >2 >2 >2 >2
H H H Br (H) H (Br) 27 >2 >2 >2 >2 >2 >2 >2
H H H H H 28 >2 >2 >2 >2 >2 >2 >2
Cl OCH3 Br Br 29 >2 >2 >2 >2 >2 >2 >2
Cl OCH3 Br H 30 >2 >2 >2 >2 >2 >2 >2
Cl OCH3 H Br 31 >2 >2 >2 >2 >2 >2 >2
Cl OCH3 H H 32 >2 >2 >2 >2 >2 >2 >2
H OCH3 Br Br 33 >2 >2 >2 >2 >2 >2 >2
H OCH3 Br H 34 >2 >2 >2 >2 >2 >2 >2
H OCH3 H Br 35 >2 >2 >2 >2 >2 >2 >2
H OCH3 H H 36 >2 >2 >2 >2 >2 >2 >2
H Cl OCH3 Br Br 37 >2 1.7 ± 0.2 >2 >2 >2 >2 >2
H Cl OCH3 Br H 38 >2 >2 >2 >2 >2 >2 >2
H Cl OCH3 H Br 39 >2 >2 >2 >2 >2 >2 >2
H Cl OCH3 H H 40 >2 >2 >2 >2 >2 >2 >2
H H OCH3 Br Br 41 >2 >2 >2 >2 >2 >2 >2
H H OCH3 Br H 42 >2 >2 >2 >2 >2 >2 >2
H H OCH3 H Br 43 >2 >2 >2 >2 >2 >2 >2
H H OCH3 H H 44 >2 >2 >2 >2 >2 >2 >2
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Table 9. Log(IC50) and Log(CC50) results and standard deviations for compounds tested 
in the human HSP60/10-dMDH folding assay and the THLE3 and HEK 293 cytotoxicity 
assays.  
 
 
 
 
 
Compound
# / Name
Closantel 0.17 ± 0.12 1.6 ± 0.2 1.8 ± 0.1
R1 R2 R3 R4 R5 Rafoxanide 0.19 ± 0.06 1.4 ± 0.1 >2
Cl OH Br Br 1 0.60 ± 0.38 1.2 ± 0.3 1.9 ± 0.2
Cl OH Br H 2 0.73 ± 0.09 1.3 ± 0.2 1.8 ± 0.3
Cl OH H Br 3 >2 1.1 ± 0.2 1.6 ± 0.2
Cl OH H H 4 >2 1.5 ± 0.10 1.8 ± 0.2
H OH Br Br 5 0.52 ± 0.05 1.3 ± 0.2 1.8 ± 0.2
H OH Br H 6 1.4 ± 0.4 1.6 ± 0.2 1.9 ± 0.2
H OH H Br 7 >2 0.99 ± 0.07 1.2 ± 0.2
H OH H H 8 >2 1.4 ± 0.1 1.8 ± 0.2
H Cl OH Br Br 9 1.4 ± 0.2 1.0 ± 0.2 1.1 ± 0.2
H Cl OH Br H 10 >2 1.2 ± 0.1 1.2 ± 0.2
H Cl OH H Br 11 >2 0.4 ± 0.1 0.4 ± 0.1
H Cl OH H H 12 >2 1.2 ± 0.2 1.1 ± 0.1
H H OH Br Br 13 1.8 ± 0.2 1.4 ± 0.1 1.4 ± 0.1
H H OH Br H 14 >2 1.8 ± 0.1 1.8 ± 0.1
H H OH H Br 15 >2 1.2 ± 0.1 1.2 ± 0.1
H H OH H H 16 >2 1.9 ± 0.1 1.9 ± 0.1
Cl H Br Br 17 >2 >2 >2
Cl H Br (H) H (Br) 18 >2 1.9 ± 0.1 >2
Cl H H H 19 >2 1.9 ± 0.1 2.0 ± 0.1
H H Br Br 20 >2 >2 >2
H H Br (H) H (Br) 21 >2 1.9 ± 0.2 1.9 ± 0.1
H H H H 22 >2 >2 >2
H Cl H Br Br 23 >2 1.7 ± 0.1 1.7 ± 0.1
H Cl H Br (H) H (Br) 24 >2 1.7 ± 0.1 1.7 ± 0.1
H Cl H H H 25 >2 >2 >2
H H H Br Br 26 >2 >2 >2
H H H Br (H) H (Br) 27 >2 >2 >2
H H H H H 28 >2 >2 >2
Cl OCH3 Br Br 29 >2 >2 >2
Cl OCH3 Br H 30 >2 >2 >2
Cl OCH3 H Br 31 >2 >2 >2
Cl OCH3 H H 32 >2 >2 >2
H OCH3 Br Br 33 >2 >2 >2
H OCH3 Br H 34 >2 >2 >2
H OCH3 H Br 35 >2 >2 >2
H OCH3 H H 36 >2 >2 >2
H Cl OCH3 Br Br 37 >2 >2 >2
H Cl OCH3 Br H 38 >2 >2 >2
H Cl OCH3 H Br 39 >2 2.0 ± 0.16 >2
H Cl OCH3 H H 40 >2 >2 >2
H H OCH3 Br Br 41 >2 >2 >2
H H OCH3 Br H 42 >2 >2 >2
H H OCH3 H Br 43 >2 >2 >2
H H OCH3 H H 44 >2 >2 >2
Compound Substituents & Substructures
Biochemical 
Assay IC50 (mM)
Cell Viability CC50 (mM)
HSP60/10-dMDH
Refolding
THLE3
(Liver)
HEK 293
(Kidney)
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Conducted grade checkups and persisted with financial obligations to more than 35 
young men which ultimately yielded 100% full payment and full re-enrollment for the 
proceeding semester for all new members. 
Inspyrewear Initiative Coordinator  November 2014-February 2015 
Organized t-shirt fundraiser on central campus of which every shirt profit in turn was 
donated to Stop Hunger Now to supply six meals for malnourished children in third world 
countries. 
Made over $1800 in sales which in turn packed and shipped more than 300 meals 
worldwide. 
Honors 
Recipient of the Northern Illinois University Emerging Leader Award          
Scholarship recipient for Northern Illinois  May 2013 
University Out of State Scholarship                                                            August 2012 
 
